CA2459869C - A system for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer - Google Patents
A system for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer Download PDFInfo
- Publication number
- CA2459869C CA2459869C CA2459869A CA2459869A CA2459869C CA 2459869 C CA2459869 C CA 2459869C CA 2459869 A CA2459869 A CA 2459869A CA 2459869 A CA2459869 A CA 2459869A CA 2459869 C CA2459869 C CA 2459869C
- Authority
- CA
- Canada
- Prior art keywords
- hormone
- concentrated
- composition
- pharmaceutical
- compounding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229940088597 hormone Drugs 0.000 title claims abstract description 179
- 239000005556 hormone Substances 0.000 title claims abstract description 179
- 238000013329 compounding Methods 0.000 title claims description 85
- 239000003814 drug Substances 0.000 title claims description 23
- 239000002904 solvent Substances 0.000 claims abstract description 57
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 36
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 36
- 239000003937 drug carrier Substances 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims description 175
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 68
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 63
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 62
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 61
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 61
- 229960001348 estriol Drugs 0.000 claims description 61
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 60
- 229930182833 estradiol Natural products 0.000 claims description 60
- 229960005309 estradiol Drugs 0.000 claims description 60
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 48
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 48
- 229960003399 estrone Drugs 0.000 claims description 48
- 239000002674 ointment Substances 0.000 claims description 47
- 239000006071 cream Substances 0.000 claims description 42
- 239000007788 liquid Substances 0.000 claims description 38
- 229960003604 testosterone Drugs 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 31
- 229960003387 progesterone Drugs 0.000 claims description 31
- 239000000186 progesterone Substances 0.000 claims description 31
- 239000000499 gel Substances 0.000 claims description 29
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 25
- 239000000262 estrogen Substances 0.000 claims description 25
- 229940011871 estrogen Drugs 0.000 claims description 25
- 239000002245 particle Substances 0.000 claims description 24
- 239000012467 final product Substances 0.000 claims description 22
- 239000000047 product Substances 0.000 claims description 20
- 230000007423 decrease Effects 0.000 claims description 17
- 239000006072 paste Substances 0.000 claims description 16
- 238000002657 hormone replacement therapy Methods 0.000 claims description 13
- 239000003270 steroid hormone Substances 0.000 claims description 13
- 239000003098 androgen Substances 0.000 claims description 11
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 11
- 239000000583 progesterone congener Substances 0.000 claims description 11
- ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 229960000249 pregnenolone Drugs 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims 62
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 claims 10
- ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 claims 5
- 239000011877 solvent mixture Substances 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 58
- 239000012141 concentrate Substances 0.000 description 57
- 229940079593 drug Drugs 0.000 description 20
- 230000001681 protective effect Effects 0.000 description 15
- 238000009472 formulation Methods 0.000 description 14
- -1 troches Substances 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 238000002156 mixing Methods 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 229960004063 propylene glycol Drugs 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000002537 cosmetic Substances 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000576 food coloring agent Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 8
- 239000000080 wetting agent Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002411 adverse Effects 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 235000019271 petrolatum Nutrition 0.000 description 6
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229960002847 prasterone Drugs 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000009423 ventilation Methods 0.000 description 5
- YUSCRGFYKCAQHE-HQFNMCNFSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;(8r,9s,13s,14s,16r,17r)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,16,17-triol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 YUSCRGFYKCAQHE-HQFNMCNFSA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 4
- 239000004264 Petrolatum Substances 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 231100001261 hazardous Toxicity 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 239000007764 o/w emulsion Substances 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 229940066842 petrolatum Drugs 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000010199 sorbic acid Nutrition 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 3
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 229940023476 agar Drugs 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 235000010338 boric acid Nutrition 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 239000004570 mortar (masonry) Substances 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000003883 ointment base Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 235000010241 potassium sorbate Nutrition 0.000 description 3
- 239000004302 potassium sorbate Substances 0.000 description 3
- 229940069338 potassium sorbate Drugs 0.000 description 3
- OZZAYJQNMKMUSD-DMISRAGPSA-N pregnenolone succinate Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 OZZAYJQNMKMUSD-DMISRAGPSA-N 0.000 description 3
- 229940083037 simethicone Drugs 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 239000003351 stiffener Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 2
- YJCJVMMDTBEITC-UHFFFAOYSA-N 10-hydroxycapric acid Chemical compound OCCCCCCCCCC(O)=O YJCJVMMDTBEITC-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 241000157282 Aesculus Species 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- 244000144725 Amygdalus communis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241001443715 Fusarium oxysporum f. sp. conglutinans Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 244000020551 Helianthus annuus Species 0.000 description 2
- 235000003222 Helianthus annuus Nutrition 0.000 description 2
- 241001367069 Hemiargus ceraunus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 244000165082 Lavanda vera Species 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 2
- 240000000353 Ruscus aculeatus Species 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 244000000231 Sesamum indicum Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002535 acidifier Substances 0.000 description 2
- 230000003113 alkalizing effect Effects 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229960002645 boric acid Drugs 0.000 description 2
- 229940119162 calendula officinalis flower extract Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 229940086555 cyclomethicone Drugs 0.000 description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- VFPFQHQNJCMNBZ-UHFFFAOYSA-N ethyl gallate Chemical compound CCOC(=O)C1=CC(O)=C(O)C(O)=C1 VFPFQHQNJCMNBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940075529 glyceryl stearate Drugs 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 239000000383 hazardous chemical Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229960004400 levonorgestrel Drugs 0.000 description 2
- 235000019136 lipoic acid Nutrition 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- 229940067107 phenylethyl alcohol Drugs 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 2
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 2
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 2
- 229940101027 polysorbate 40 Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 229940096792 quaternium-15 Drugs 0.000 description 2
- UKHVLWKBNNSRRR-TYYBGVCCSA-M quaternium-15 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C/C=C/Cl)C3 UKHVLWKBNNSRRR-TYYBGVCCSA-M 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 2
- 235000011071 sorbitan monopalmitate Nutrition 0.000 description 2
- 239000001570 sorbitan monopalmitate Substances 0.000 description 2
- 229940031953 sorbitan monopalmitate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 229960002663 thioctic acid Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960004418 trolamine Drugs 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 229940045860 white wax Drugs 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 229940078693 1-myristylpicolinium Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- MUJHZQRRTJXWOT-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;propanoic acid Chemical compound CCC(O)=O.OC(=O)C(O)C(O)C(O)=O MUJHZQRRTJXWOT-UHFFFAOYSA-N 0.000 description 1
- XRIBIDPMFSLGFS-UHFFFAOYSA-N 2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(C)CO XRIBIDPMFSLGFS-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 1
- BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- IDSIQQMLAHZIDR-UHFFFAOYSA-N 3-hydroxy-1h-quinolin-2-one;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2NC(=O)C(O)=CC2=C1 IDSIQQMLAHZIDR-UHFFFAOYSA-N 0.000 description 1
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 1
- KFZXVMNBUMVKLN-UHFFFAOYSA-N 4-chloro-5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC(Cl)=C(C)C=C1O KFZXVMNBUMVKLN-UHFFFAOYSA-N 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZCTSINFCZHUVLI-UHFFFAOYSA-M 4-methyl-1-tetradecylpyridin-1-ium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+]1=CC=C(C)C=C1 ZCTSINFCZHUVLI-UHFFFAOYSA-M 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000219496 Alnus Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical class OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 241000722877 Borago Species 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- JUQPZRLQQYSMEQ-UHFFFAOYSA-N CI Basic red 9 Chemical compound [Cl-].C1=CC(N)=CC=C1C(C=1C=CC(N)=CC=1)=C1C=CC(=[NH2+])C=C1 JUQPZRLQQYSMEQ-UHFFFAOYSA-N 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- QMBJSIBWORFWQT-DFXBJWIESA-N Chlormadinone acetate Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 QMBJSIBWORFWQT-DFXBJWIESA-N 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000009849 Cucumis sativus Nutrition 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- GHKOFFNLGXMVNJ-UHFFFAOYSA-N Didodecyl thiobispropanoate Chemical compound CCCCCCCCCCCCOC(=O)CCSCCC(=O)OCCCCCCCCCCCC GHKOFFNLGXMVNJ-UHFFFAOYSA-N 0.000 description 1
- 239000003508 Dilauryl thiodipropionate Substances 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- 239000004262 Ethyl gallate Substances 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 description 1
- 108010058643 Fungal Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 235000000072 L-ascorbyl-6-palmitate Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 235000002997 Lavandula Nutrition 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 235000010649 Lupinus albus Nutrition 0.000 description 1
- 240000000894 Lupinus albus Species 0.000 description 1
- 235000017011 Mandorlo dulce Nutrition 0.000 description 1
- 244000076313 Mandorlo dulce Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002669 Polyoxyl 20 Cetostearyl Ether Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Natural products OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- FHNINJWBTRXEBC-UHFFFAOYSA-N Sudan III Chemical compound OC1=CC=C2C=CC=CC2=C1N=NC(C=C1)=CC=C1N=NC1=CC=CC=C1 FHNINJWBTRXEBC-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- OFUHPGMOWVHNPN-QWZFGMNQSA-N [(2r)-2,5,7,8-tetramethyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-yl] (9z,12z)-octadeca-9,12-dienoate Chemical compound O1[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CCC2=C(C)C(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)=C(C)C(C)=C21 OFUHPGMOWVHNPN-QWZFGMNQSA-N 0.000 description 1
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- CQPFMGBJSMSXLP-UHFFFAOYSA-M acid orange 7 Chemical compound [Na+].OC1=CC=C2C=CC=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 CQPFMGBJSMSXLP-UHFFFAOYSA-M 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 229940031955 anhydrous lanolin Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- 229940052223 basic fuchsin Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 229960003872 benzethonium Drugs 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 125000005619 boric acid group Chemical class 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- LVGQIQHJMRUCRM-UHFFFAOYSA-L calcium bisulfite Chemical compound [Ca+2].OS([O-])=O.OS([O-])=O LVGQIQHJMRUCRM-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000010260 calcium hydrogen sulphite Nutrition 0.000 description 1
- GBAOBIBJACZTNA-UHFFFAOYSA-L calcium sulfite Chemical compound [Ca+2].[O-]S([O-])=O GBAOBIBJACZTNA-UHFFFAOYSA-L 0.000 description 1
- 235000010261 calcium sulphite Nutrition 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940099417 ceramide 2 Drugs 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229940048851 cetyl ricinoleate Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- ONTQJDKFANPPKK-UHFFFAOYSA-L chembl3185981 Chemical compound [Na+].[Na+].CC1=CC(C)=C(S([O-])(=O)=O)C=C1N=NC1=CC(S([O-])(=O)=O)=C(C=CC=C2)C2=C1O ONTQJDKFANPPKK-UHFFFAOYSA-L 0.000 description 1
- 229960001616 chlormadinone acetate Drugs 0.000 description 1
- 229940031956 chlorothymol Drugs 0.000 description 1
- 229960005443 chloroxylenol Drugs 0.000 description 1
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940035810 combination estradiol Drugs 0.000 description 1
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940075482 d & c green 5 Drugs 0.000 description 1
- 229940099458 d&c green no. 8 Drugs 0.000 description 1
- 229940099449 d&c orange no. 4 Drugs 0.000 description 1
- 229940056316 d&c red no. 28 Drugs 0.000 description 1
- 229940075493 d&c red no. 6 Drugs 0.000 description 1
- 229940096890 d&c violet no. 2 Drugs 0.000 description 1
- 229940051157 d&c yellow no. 11 Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 235000019304 dilauryl thiodipropionate Nutrition 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- SIYLLGKDQZGJHK-UHFFFAOYSA-N dimethyl-(phenylmethyl)-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethyl]ammonium Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 SIYLLGKDQZGJHK-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- VPWFPZBFBFHIIL-UHFFFAOYSA-L disodium 4-[(4-methyl-2-sulfophenyl)diazenyl]-3-oxidonaphthalene-2-carboxylate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1N=NC1=C(O)C(C([O-])=O)=CC2=CC=CC=C12 VPWFPZBFBFHIIL-UHFFFAOYSA-L 0.000 description 1
- LQJVOKWHGUAUHK-UHFFFAOYSA-L disodium 5-amino-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(N)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 LQJVOKWHGUAUHK-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- ZBZFFMBWUCAHIW-UHFFFAOYSA-L disodium propan-2-one sulfate Chemical compound [Na+].[Na+].CC(C)=O.[O-]S([O-])(=O)=O ZBZFFMBWUCAHIW-UHFFFAOYSA-L 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- FPAYXBWMYIMERV-UHFFFAOYSA-L disodium;5-methyl-2-[[4-(4-methyl-2-sulfonatoanilino)-9,10-dioxoanthracen-1-yl]amino]benzenesulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1S([O-])(=O)=O FPAYXBWMYIMERV-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229960000878 docusate sodium Drugs 0.000 description 1
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000010776 emu oil Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 229940057841 eosine yellowish Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- YZSJUQIFYHUSKU-UHFFFAOYSA-N ethanol;propane-1,2-diol Chemical compound CCO.CC(O)CO YZSJUQIFYHUSKU-UHFFFAOYSA-N 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019277 ethyl gallate Nutrition 0.000 description 1
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 229940089020 evening primrose oil Drugs 0.000 description 1
- 239000010475 evening primrose oil Substances 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 229960005352 gestodene Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000003969 glutathione Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- SFFVATKALSIZGN-UHFFFAOYSA-N hexadecan-7-ol Chemical compound CCCCCCCCCC(O)CCCCCC SFFVATKALSIZGN-UHFFFAOYSA-N 0.000 description 1
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 1
- 229940119204 hibiscus sabdariffa flower extract Drugs 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229960004337 hydroquinone Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- GQZXNSPRSGFJLY-UHFFFAOYSA-N hydroxyphosphanone Chemical compound OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940046817 hypophosphorus acid Drugs 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 235000011475 lollipops Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- 229940002712 malachite green oxalate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940100630 metacresol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940043265 methyl isobutyl ketone Drugs 0.000 description 1
- 229940073584 methylene chloride Drugs 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 108700019599 monomethylolglycine Proteins 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- UEHLXXJAWYWUGI-UHFFFAOYSA-M nitromersol Chemical compound CC1=CC=C([N+]([O-])=O)C2=C1O[Hg]2 UEHLXXJAWYWUGI-UHFFFAOYSA-M 0.000 description 1
- 229940118238 nitromersol Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229920004918 nonoxynol-9 Polymers 0.000 description 1
- 229940087419 nonoxynol-9 Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 229960001652 norethindrone acetate Drugs 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 235000010387 octyl gallate Nutrition 0.000 description 1
- 239000000574 octyl gallate Substances 0.000 description 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940032051 peg-8 distearate Drugs 0.000 description 1
- 239000003209 petroleum derivative Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 229940043349 potassium metabisulfite Drugs 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- KXXXUIKPSVVSAW-UHFFFAOYSA-K pyranine Chemical compound [Na+].[Na+].[Na+].C1=C2C(O)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 KXXXUIKPSVVSAW-UHFFFAOYSA-K 0.000 description 1
- TVRGPOFMYCMNRB-UHFFFAOYSA-N quinizarine green ss Chemical compound C1=CC(C)=CC=C1NC(C=1C(=O)C2=CC=CC=C2C(=O)C=11)=CC=C1NC1=CC=C(C)C=C1 TVRGPOFMYCMNRB-UHFFFAOYSA-N 0.000 description 1
- 229940051201 quinoline yellow Drugs 0.000 description 1
- 235000012752 quinoline yellow Nutrition 0.000 description 1
- IZMJMCDDWKSTTK-UHFFFAOYSA-N quinoline yellow Chemical compound C1=CC=CC2=NC(C3C(C4=CC=CC=C4C3=O)=O)=CC=C21 IZMJMCDDWKSTTK-UHFFFAOYSA-N 0.000 description 1
- FZUOVNMHEAPVBW-UHFFFAOYSA-L quinoline yellow ws Chemical compound [Na+].[Na+].O=C1C2=CC=CC=C2C(=O)C1C1=NC2=C(S([O-])(=O)=O)C=C(S(=O)(=O)[O-])C=C2C=C1 FZUOVNMHEAPVBW-UHFFFAOYSA-L 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 229940081623 rose bengal Drugs 0.000 description 1
- 229930187593 rose bengal Natural products 0.000 description 1
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 description 1
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229960005369 scarlet red Drugs 0.000 description 1
- RCTGMCJBQGBLKT-PAMTUDGESA-N scarlet red Chemical compound CC1=CC=CC=C1\N=N\C(C=C1C)=CC=C1\N=N\C1=C(O)C=CC2=CC=CC=C12 RCTGMCJBQGBLKT-PAMTUDGESA-N 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940101011 sodium hydroxymethylglycinate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229960000819 sodium nitrite Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- LJFWQNJLLOFIJK-UHFFFAOYSA-N solvent violet 13 Chemical compound C1=CC(C)=CC=C1NC1=CC=C(O)C2=C1C(=O)C1=CC=CC=C1C2=O LJFWQNJLLOFIJK-UHFFFAOYSA-N 0.000 description 1
- 150000003398 sorbic acids Chemical class 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940099373 sudan iii Drugs 0.000 description 1
- 229940044609 sulfur dioxide Drugs 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 229940119168 tetrahexyldecyl ascorbate Drugs 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 1
- 229960004224 tyloxapol Drugs 0.000 description 1
- 229920001664 tyloxapol Polymers 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Abstract
The invention concerns a concentrated hormone pharmaceutical composition having from about 0.6 to about 80% of at least one hormone; from about 20 to about 90.4% of at least one solvent, and optionally a pharmaceutically acceptable carrier. The concentrated hormone pharmaceutical composition according to this invention provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products. In addition, provides a pharmaceutical composition having a higher concentration of hormone than the concentration found in the BHRT pharmaceutical products of the prior art.
Description
CA 2,459,869 CA 02459869 2009-05-21 A SYSTEM FOR USE BY COMPOUNDING PHARMACISTS
TO PRODUCE HORMONE REPLACEMENT MEDICINE
CUSTOMIZED FOR EACH CONSUMER
BACKGROUND OF THE INVENTION
Field of the Invention [0001] This invention relates to a concentrated hormone pharmaceutical composition to be use d in the production of hormone replacement therapy.
Description of the Related Art
TO PRODUCE HORMONE REPLACEMENT MEDICINE
CUSTOMIZED FOR EACH CONSUMER
BACKGROUND OF THE INVENTION
Field of the Invention [0001] This invention relates to a concentrated hormone pharmaceutical composition to be use d in the production of hormone replacement therapy.
Description of the Related Art
[0002] Natural hormone replacement satrapy has been around for more than twenty years.
The term "natural" comes from the fact that the hormones (estrogens such as estradiol, estrone, and estriol, testosterone, DHEA, pregnenolone and progesterone) come from natural sources. However, more importantly, the term means that the hormones have the exact same molecular structure as those produced by the body itself, thus the body recognizes the hormones as being "natural", because they are "bio-identical".
Therefore, the shift to a more appropriate name, Bio-identical Hormone Replacement Therapy (BHRT).
The term "natural" comes from the fact that the hormones (estrogens such as estradiol, estrone, and estriol, testosterone, DHEA, pregnenolone and progesterone) come from natural sources. However, more importantly, the term means that the hormones have the exact same molecular structure as those produced by the body itself, thus the body recognizes the hormones as being "natural", because they are "bio-identical".
Therefore, the shift to a more appropriate name, Bio-identical Hormone Replacement Therapy (BHRT).
[0003] Some of the benefits of BHRT include: fewer side effects compared with traditional HRT; protection against heart disease, reduced risk of breast cancer, and improved lipid profile.
[0004] Bio-identical Hormone Replacement Therapy products are compounded by a compounding pharmacist, which offers you and your physician a choice for individualized hormone replacement. General, the BHRT pharmaceutical compositions are sold in the form of ointments, creams, gels, pastes, capsules, troches, lozenges, lollipops, tablet triturates, sublingual tablets and tablets.
{0006]A BHRT ointment, cream, gel, or paste may include, but is not limited to, the active hormone or hormones, a suitable solvent or solvents, including, but not limited to, ethoxy diglycol, propylene glycol, alcohol, or glycerin and any suitable ointment, cream, or gel base which allows for transdermal absorption of bio-identical hormones.
[0007]Producing BHRT pharmaceutical compositions is a very lucrative business for compounding pharmacies. However, the process of producing the BHRT pharmaceutical compositions is an extremely time-consuming process and has many risks and subsequent costs associated with the compounding of BHRT
pharmaceutical compositions.
[0008]One of the main problems with compounding BHRT
pharmaceutical compositions is the substantial risk of employee contamination (inhalation or transdermal absorption of the hormones) with the hormones. The hormones used for producing the BHRT pharmaceutical compositions are naturally found in the body in physiological levels. Thus, when a human is chronically exposed to higher than normal levels of these hormones, they are at risk of developing serious adverse medical effects, including, but not limited to, an unnatural increased response by each system of the body which is affected by each individual hormone, as well as an increased risk of developing numerous varieties of cancer.
[0009] In addition, producing these BHRT pharmaceutical compositions requires great skill and knowledge. It also requires expensive equipment such as accurate electronic scales, electronic mortars and pestles (EMP), and ointment mills.
[00010] In order to diminish these risks, the compounding pharmacies have developed an expensive and time-consuming method to reduce employee exposure to these hormones. These measures include, but are not limited to, the use of a custom built clean room, high velocity air flow units fitted with high emission particulate air (HEPA) filters, custom built ventilation systems, protective suits, protective eyewear, protective gloves, and protective HEPA filter masks.
[00011] The production of BHRT pharmaceutical compositions is by itself a time-consuming process. Each ointment, cream, gel, or paste must be specifically engineered for each patient based on his or her distinct hormone profile, thus the use of bulk compounding is precluded, because each medication is produced custom fit for each patient.
[00012] Furthermore, bulk compounding or manufacturing of hormone products is illegal in most states without a proper license.
[00013] In order to produce these BHRT pharmaceutical compositions safely and accurately, compounding pharmacies need to invest a great deal of time and money into these safety measures. The pharmacies would also need to employ a specially trained staff; all these measures decrease productivity substantially.
[00014] These measures are not only expensive, but also create an unpleasant work environment. This is due to the fact that the employee is covered from head to toe in restrictive, uncomfortable protective gear. They are also working in a room, which is noisy because of the high velocity ventilation systems, which are in constant use.
[00015] In order to work with BHRT pharmaceutical compositions, an employee must:
Be trained in the art of compounding BHRT ointments, creams, gels, and pastes.
Ensure they are wearing all the necessary protective gear.
Locate all of the ingredients.
Weigh all of the ingredients in the appropriate environment, a clean room with proper ventilation and filtration systems, to prevent exposure to harmful chemicals.
Combine the ingredients using the EMP to ensure thorough mixing. If the mixture is not thoroughly mixed, then it will not contain a uniform concentration of the drug throughout.
Run the mixture through an ointment mill to decrease the particle size of the drug. This will increase absorbability, as smaller drug particles will more readily penetrate the dermis. This process also ensures a non-gritty, pharmaceutically elegant, and cosmetically pleasing final product.
[00016] The combination of the potential risks associated with producing BHRT pharmaceutical compositions, specially trained employees to compound these compositions safely and accurately, purchasing all the necessary equipment and safety measures, and the actual time required to compound each individual pharmaceutical composition result in an .extremely time-consuming, hazardous, and expensive process.
[00017] The present inventor thought of the necessity of providing pharmacies with a system that is easy to use and saves time and money for those pharmacies dealing with BHRT
pharmaceutical products while decreasing risk and increasing product quality.
SUNMARY OF THE INVENTION
[00018] The invention offers at least one of the following advantages:
provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.
provides a pharmaceutical composition having a higher concentration of hormone than the concentration found in the BHRT pharmaceutical products of the prior art.
provides a pharmaceutical composition that can be used by the compounding pharmacist safely, accurately, quickly.
provides an inexpensive pharmaceutical composition with individualized BHRT products such as ointments, creams, gels, or pastes.
provides a color-coded hormone pharmaceutical composition.
[00019] The concentrated composition of the present invention can be manufactured to contain a higher concentration of hormone (or combination of hormones) than the standard concentration of hormones prescribed by physicians, thus the pharmacist can easily measure the amount required to be incorporated into the EHRT product.
[00020] The concentrated composition of the present invention could include any concentration of any hormone or any combination of hormones in any proportion as long as the concentration is greater than the accepted physician prescribed concentrations to treat hormone deficiencies.
[00021] The present invention also relates to a metered dispensing device including the composition of the invention to provide a means to measure and combine, quickly and accurately, quantities of hormones with appropriate ointment, cream, or gel bases by the compounding pharmacist while minimizing exposure to hazardous airborne hormone particles. Thus, airborne particles are drastically reduced because the hormones are incorporated into a liquid or semi-solid form.
[00022] The present invention relates to a concentrated hormone Pharmaceutical composition comprising:
from about 0.6 to about 80% of at least one hormone;
from about 20 to about 90.4 % of at least one solvent, and optionally a pharmaceutically acceptable carrier.
[00023] In the preferred embodiment, the concentrated hormone pharmaceutical composition is chosen from estradiol, estrone, estriol, testosterone, DHEA, pregnenolone, progesterone, or combination thereof.
[00024] The invention also relates to a concentrated hormone pharmaceutical composition comprising:
from about 0.6 to about 50% of at least one hormone;
from about 50 to about 90.4 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is chosen from estriol, estradiol, or combination thereof.
[00025] The at least one hormone is a combination of estriol and estradiol in a ratio of 5:5, 6:4, 7:3, 8:2, or 9:1.
[00026] Furthermore, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.6 to about 50% of at least one hormone;
from about 50 to about 90.4 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is chosen from estriol, estradiol, estrone, or combination thereof.
[00027] The at least one hormone is a combination of estriol, estradiol, and estrone in a ratio of 5:4:1, 6:3:1, 7:2:1, or 8:1:1.
[00028] Furthermore, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.8 to about 80% of at least one hormone;
from about 20 to about 90.2 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is testosterone.
[00029] In addition, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 8 to about 90% of at least one hormone;
from about 10 to about 92 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is progesterone.
[00030] Furthermore, the invention concerns to a color-coded concentrated hormone pharmaceutical.
[00031] Furthermore, the invention concerns a method for producing a concentrated hormone pharmaceutical composition, the method comprising the steps of:
measuring at least one hormone, a solvent and/or optionally a carrier by using an electronic balance in a clean room;
combining the ingredients of step a by using an industrial scale mixer to ensure thorough mixing; and running the mixture of step b through a large-scale ointment mill or homogenizer to decrease the particle size of the drug, and optionally, heating the concentrate to facilitate the formation of a solution, wherein the hormone concentration is from about 0.6 to about 80%.
WOOM Furthermore, the present invention concerns a concentrated hormone pharmaceutical composition comprising:
at least one hormone;
optionally a powdered base;
wherein the at least one hormone is chosen from estriol, estradiol, estrone, or combination thereof; and wherein the composition is in a powdered form.
[00033] Finally, the invention concerns a kit for producing a liquid or semi-solid concentrated hormone pharmaceutical composition, the kit comprising:
at least one hormone;
at least one solvent, and optionally a pharmaceutically acceptable carrier, wherein each element is packet in separated graduated dispensing devices.
[00034] The foregoing has outlined rather broadly the more pertinent and important features of the present invention in order that the detailed description of the invention that follows may be better understood, and so that the present contribution to the art can be more fully appreciated.
Additional features of the invention that will be described hereinafter form the subject matter of the claims of the invention. It should be appreciated by those skilled in the art that the conception and the specific embodiments disclosed might be readily utilized as a basis for modifying or formulating other liquid formulations for carrying the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent formulations do not depart from the spirit and scope of the invention as set forth in the appended claims.
DETAILED DESCRIPTION OF THE INVENTION
[00035] The present invention concerns a pharmaceutical composition, including high concentrations of hormone that can be used by the compounding pharmacist safely, accurately, quickly, and inexpensively to produce individualized BHRT products such as ointments, creams, gels, or pastes.
[00036] The present invention concerns a concentrated hormone pharmaceutical composition comprising:
at least one hormone;
at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the weight concentration of the at least one hormone in said composition is equal or greater than 0.6%.
[00037] In one of the embodiments, the concentrated is in a powdered form.
[00038] The term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
Hormones [00039] The present invention contemplates the use of any one of the steroid hormones derived from cholesterol including, but not limited to, estrogen (estriol, estradiol, or estrone), progesterone, testosterone, dehydroepiandrosterone, norethisterone acetate, norgestrel, levonorgestrel gestodene CPA chlormadinone acetate, drospirorenone, and 3-ketodesogestrel.
[00040] The concentrates also could include, but not be limited to, an estriol concentrate, an estradiol concentrate, an estrone concentrate, a combination estriol, estradiol, and estrone (triest) concentrate in any proportion, preferably in a 8:1:1, 5:4:1, 6:3:1, or 7:2:1 ratio; a combination of estriol and estradiol concentrate (blest) in any proportion, preferably in a 5:5, 6:4, 7:3, CA 02459869 2004-05-18 , 8:2, or 9:1 ratio; a combination estriol and estrone concentrate, a combination estradiol and estrone concentrate, a progesterone concentrate, a combination progesterone and estriol concentrate, a combination progesterone and estradiol concentrate, a combination progesterone and estrone concentrate, a combination progesterone and triest concentrate, a combination progesterone, estriol, and estradiol concentrate, a combination progesterone, estriol, and estrone concentrate, a combination progesterone estradiol, and estrone concentrate, any of the previously mentioned concentrates in combination with testosterone i.e. a combination triest, progesterone, and testosterone concentrate, a testosterone concentrate, any of the previously mentioned concentrates in combination with dehydroepiandrosterone (DHEA), and a DHEA
concentrate.
[00041] In addition, any of the sex hormones may be used.
Any androgen including, but not limited to, testosterone may be used. Any progestogen including, but not limited to, progesterone may be used. Any estrogen including, but not limited to, estriol, estradiol, or estrone may be used.
[00042] The concentrated composition of the present invention could include any concentration of any hormone or any combination of hormones in any proportion as long as the concentration is greater than the accepted physician prescribed concentrations to treat hormone deficiencies.
[00043] The present invention provides a concentrated pharmaceutical composition that contains any ratio of estriol to estradiol (biest) having between 6 mg/g and 900 mg/g of biest, preferably between 8 mg/g and 200 mg/g, even more preferably 10mg/g to 60 mg/g.
[00644] In addition, the present invention provides a concentrated pharmaceutical composition that contains any ratio of estriol, estradiol, and estrone (triest) having between 6 mg/g and 900 mg/g of the triest, preferably between 8 mg/g and 200 mg/g, even more preferably 10 mg/g and 60 mg/g.
[00045] Furthermore, the present invention provides a concentrated pharmaceutical composition that contains between 10 mg/g and 900 mg/g of estriol, preferably between 15 mg/g and 300 mg/g, even more preferably 15 and 60 mg/g.
[00046] The present invention provides a concentrated pharmaceutical composition that contains between 1 mg/g and 900 mg/g of estradiol, preferably between 1.5 mg/g and 100 mg/g.
[00047] The present invention also provides a concentrated pharmaceutical composition that contains between 1 mg/g and 900 mg/g of estrone, preferably between 1.5 mg/g and 100 mg/g.
[00048] In addition, the present invention provides a concentrated pharmaceutical composition that contains between 10 mg/g and 800 mg/g of testosterone, preferably between 15 mg/g and 900 mg/g, even more preferably between 15 mg/g and 300 mg/g, for use in a female BHRT product.
[00049] Furthermore, the present invention provides a concentrated pharmaceutical compound that contains between 100 mg/g and 900 mg/g of testosterone, for use in a male BHRT product.
[00050] In addition, the present invention provides a concentrated pharmaceutical compound that contains between 200 mg/g and 900 mg/g of progesterone, more preferably between 400 mg/g and 800 mg/g, even more preferably 600mg/g.
[00051] Furthermore, the present invention provides a concentrated pharmaceutical compound that contains between mg/g and 900 mg/g of dehydroepiandrosterone or between 30 mg/g to 800 mg/g of pregnenolone.
[00052] The invention also concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.6 to about 50% of at least one hormone;
from about 50 to about 90.4 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is chosen from estriol, estradiol, or combination thereof.
[00053] In addition, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.6 to about 50% of at least one hormone;
and from about 50 to about 90.4 % of at least one solvent, optionally a pharmaceutically acceptable carrier wherein the at least one hormone is chosen from estriol, estradiol, estrone, or combination thereof.
[00054] Furthermore, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.8 to about 80% of at least one hormone;
from about 20 to about 90.2 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is testosterone.
R0059 The invention also concerns a concentrated hormone pharmaceutical composition comprising:
from about 8 to about 90% of at least one hormone;
from about 10 to about 92 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is progesterone.
Solvent (or Wetting agent) [00056] The solvent or wetting agent can be any liquid that can dissolve, partially dissolve, wet, or suspend the hormone, or reduce the surface tension of a liquid to a value below the hormones critical surface tension.
[00057] In order for a solid to be incorporated into a liquid, the solids surface tension must be above the surface tension of the liquid. The best solvents produce a low air liquid surface tension, and are not readily adsorbed by the solid so as to produce nonwetting behavior.
ROOM The wetting agent or solvent acts by lowering the contact angle between the surface of the particle and the wetting liquid. Wetting agents replace a solid to air interface with a solid to liquid interface. The solvent or wetting agent should be miscible with the carrier.
[00059] The solvent or wetting agent could possibly be, but is not limited to, one or more of the following in any concentration: propylene glycol, ethoxy diglycol, glycerin, mineral oil, fixed oil, emu oil, peanut oil, vitamin E oil, acetone, amylene hydrate, benzyl benzoate, corn oil, cottonseed oil, diethylene glycol monoethyl ether, ethyl acetate, isopropyl alcohol, methyl alcohol, methylene chloride, methyl isobutyl ketone, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, sesame oil, alcohol, a 50% ethoxy diglycol (diethylene glycol mono-ehyletherand) 50% propylene glycol mixture, water or mixtures threrof. Any combination of solvents may be employed.
gmow The solvent or wetting agent should satisfy the following characteristics:
the solvent or solvents should wet the hormone;
the solvent should allow the hormone to be incorporated therein;
the solvent or solvents should be compatible with the skin with the least possible number of adverse effects;
the solvent or solvents should be smooth and pliable with no adverse odor;
the solvent or solvents should have a color appealing to the consumer; and the solvent must be stable and must provide a stable vehicle for the medication.
[00061] The scope of the present invention is not limited by the solvents mentioned in the present application; any of those known in the pharmaceutical and cosmetic industries may be employed.
Pharmaceutically acceptable Carrier [00062] The carrier can be any suitable carrier that can be incorporated into a system, which can deliver bio-identical hormones transdermaly.
[00063] The formulations for the delivery of the pharmaceutical composition according to the present invention may be liquid, ointments, and creams.
gmoGc The carrier can be chosen from ointment base, powder base, cream base, or a gel base.
[00065] Ointments are semisolid preparations, which are typically based on petrolatum or other petroleum derivatives. Creams containing the selected active agent, are, as known in the art, viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil.
[00066] Cream bases are water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, also sometimes called the "internal" phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
[00067] The specific ointment or cream base to be used, as will be appreciated by those skilled in the art, is one that will provide for optimum drug delivery. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and non-sensitizing.
[00068] Powders may be formulated with the aid of any suitable powder base, such as talc, lactose, starch, and the like.
gmow The pharmaceutical carrier could possibly be comprised of, but is not limited to, any or all of the following ingredients: an oil in water emulsion base, a water in oil emulsion base, an oleaginous base, an absorption base, a water soluble base an anhydrous gel, a pluronic F127/lecithin isopropyl palmitate gel, hydrous gel, purified water, white petrolatum, cetearyl alcohol, ceteareth-20, sorbitol solution, propylene glycol, simethicone, glyceryl monostearate, polyethylene glycol monostearate, sorbic acid, camellia sinensis (green tea) leaf extract, cholesterol, beeswax, cyclomethicone, C 12-15 alkyl benzoate, plankton extract, acetyl ponta peptide-2, ocnethera biennis (evening primrose) root extract, dimethicone, hexyldecanol, dextran, stearyl alcohol, cetyl alcohol, pyrus malus (apple) fruit extract, acetyl hexapeptide-2, alnus firmirolia (yashabushi) extract, tocopheryl acetate (vitamin E acetate), glyceryl stearate, thioctic acid (a-lipoic acid), PEG-100 stearate, ascorbyl palmitate ( vitamin C palmitate), tocopherol (vitamin E), tetrahexyldecyl ascorbate, sesamum indicum (sesame) seed oil, retinyl palmitate (vitamin A palmitate), Prunus armeniaca (apricot) kernel oil, willow bark extract, phenoxyethanol, benzyl alcohol, potassium sorbate, glycerin, panthenol (pro-vitamin B5), retinal (vitamin A), lavandula agustifolia (lavender) oil, allantoin, polysorbate 20, xanthan gum, titanium dioxide, tetrasodium EDTA, topheryl linoleate (vitamin E linoleate), dimethylamino methylpropanol, ceramide 2, quaternium-15, polyacrylamide, magnesium aluminum silicate, laureth-7, citric acid, C13-14 isoparaf fin, aloe barbadensis (aloe vera) leaf juice, cetearyl glucoside, 10-hydroxydecanoic acid, hydroxycaprylic acid, prunus amygdalus dulcis (sweet almond)oil, zinc PCA, zinc oxide, acacia, tragacanth, agar, pectin, gelatin, methyl cellulose, carboxymethylcellulose, carbomer, vitis vinifera (grape) seed extract, hibiscus sabdariffa flower extract, triticum vulgare (wheat)germ oil, citic acid, sodium hydroxymethylglycinate, isopropyl palmitate, squalane, cetearyl glucoside, lecithin, pluronic, cucumis sativus (cucumber) fruit extract, cetyl ricinoleate, caprylic/capric triglycerides, allantoin, ubiquinone (coenzyme Q10), helianthus annuus (hybrid sunflower) oil, cyclomethicone sodium PCA, stearic acid, glyceryl stearate, rose canina (rose hips) fruit oil, glycol, glycyrrhiza glabra (licorice) extract,aesculus hippacastanum (horse chestnut)extract, hydrolyzed yeast protein, calendula off icinalis flower extract, centella asiatica (gotu kola) extract, ruscus aculeatus (butcher's broom)root extract, cyclopentasiloxane, evening primrose oil, PEG-75, PEG-150, sodium PCA, calendula officinalis flower extract, cyclopentasiloxane, hydrolyzed milk protein, ethoxy diglycol, lupinus albus seed oil, hydrophilic petrolatum, wool alcohol, sodium lauryl sulfate, PEG 4000, PEG 400, propylene glycol-ethanol, lecithin soya granular, sorbic acid, polyacrylamide, cytel alcohol, magnesium aluminum silicate, aloe vera (aloe barbadensis) prunus amygadalus amara (bitter almond) kenel oil, pro-lipo multi-emulsion liposomic system, propylparaben, methylparaben, imidazolidimyl urea, pluronic F127, alcohol, sodium hydroxide, DMAE, glycolic acid, edetate disodium dihydrate, urea, stearic acid, glyceryl monostearate, isopropyl myristate, polyoxyl 40 stearate, potassium sorbate, anhydrous ointment base, lanolin, anhydrous lanolin, emollient cream base, lanolin alcohol, mineral oil, glyceryl monostearate, stearic acid flakes, sualene, triethanolamine, krisgel 100, borago (borage) officinalis seed oil, simethicone, salicylic acid, dehydroacetic acid, benzyl alcohol, benzoic acid, benzethonium chloride, polysorbate 80, span, PEG-8 distearate/emerest 2712, hydrogenated vegetable oil, mineral oil (heavy), mineral oil (light), microethane FN 501, hydroxypropylcellulose, hydroxymethylcellulose, methylcellulose, avicel, polyglygol 300, polyglycol 8000, paraffin waxes, propylene glycol isostearate, isostearyl alcohol, white ointment USP, yellow ointment NF, oleic acid USP, olive oil USP, paraffin USP, petrolatum NF, spermaceti wax USP, synthetic spermaceti NF, starch glycerite NF, white wax USP, yellow wax USP, dbutylated hydroxy toluene, or combination thereof.
tamm The carrier should satisfy the following characteristics:
the base should allow the wetted hormone to be incorporated therein;
the base should be compatible with the skin with the least possible number of adverse effects;
the base should be smooth and pliable with no adverse odor;
the base should have a color appealing to the consumer;
the base must be stable and must provide a stable vehicle for the medication; and the base should be able to readily release the medication incorporated therein into the skin.
Additional Ingredients [00071] The concentrated pharmaceutical composition according to the invention optionally can include antioxidants to prevent oxidation of any of the components therein. The antioxidant may include, but are not limited to, ascorbic acid, sodium ascorbate, sodium formaldehyde sulfoxylate, sodium bisulfite, sodium nitrite, sodium thiosulfate, sodium metabisulfite, sodium sulfite, sulfur dioxide, tannic acid, thioglycerol, tert-butyl-hydroquinone, thioglycolic acid, thiolactic acid, thiosorbitol, thiourea, tocopherols, butylated hydroxy toluene, acetone sodium sulfate, acetylcysteine, lipoic acid (sodium salt), tocopherol, ascorbyl palmitate, butylated hydroxyanisole, calcium ascorbate, calcium bisulfite, calcium sulfite, . cysteine, dilauryl thiodipropionate, dithiothreitol,dodecyl gallate, ethoxyquin, ethyl gallate, gallic acid, glutathione, gossypol, hydroquinone,4-hydroxymethy1-2,6-di-tert-butylphenol, hypophosphorus acid, isoascorbic acid, lecithin, monothioglycerol, B-naphthol, nordihydroguaiaretic acid, octyl gallate, potassium metabisulfite, propyl gallate, sesamol, or Vitamin E. These antioxidants are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00072] In addition, the concentrated pharmaceutical composition according to the invention optionally may include preservatives to prevent the growth of bacteria or fungi in the final product. These may include, but are not limited to, thimerosal, benzyl alcohol, imidazolidinyl urea, quaternium-15, benzalkonium chloride, chlohexidine, chlorbutanol, phenol, cresol, chlorothymol, chloroxylenol, P-chlorometaxylenol, sodium benzoate, potassium sorbate, boric acid, methyl paraben, propylparaben, sorbic acid, alcohol, benzethonium chloride, benzoic acids and salts, benzyl alcohol, sodium benzoate, boric acids and salts, cetylpyridinium chloride, cetyltrimethyl ammonium bromide, chlorbutanol, clorocresol, imidazolidinyl urea, metacresol, myristylgamma picolinium chloride, nitromersol, parabens(benzyl, butyl, methyl, propyl), phenol, phenyl phenol, phenylethyl alcohol, phenylmercuric acetate/nitrate, sorbic acids and salts, thimerosal, hydroxybezoate esters and phenyl ethyl alcohol. These preservatives are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00073] Further, the concentrated composition of the invention optionally can include chelating agents and synergists added, which may include, but are not limited to, EDTA and salts, alkyl gallates, ascorbic acid, boric acid, citraconic acid, gluconic acid, hydroxyquinolone sulfate, maleic acid, phosphoric acid, polysorbates, saccharic acid, tartaric acid, tryptophan and citric acid. These chelating agents and synergists are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00074] Further, the concentrated composition of the invention optionally can include emulsifying agents to facilitate the formation of an emulsion. The emulsifying agents may include, but are not limited to acacia, tragacanth, agar, pectin, gelatin, methyl cellulose, carboxymethylcellulose, PEG-40 castor oil, PEG 300, polysorbate 20, polysorbate 40, polysorbate 80, sorbitan monopalmitate, simethicone, or any synthetic anionic, cationic, or nonionic emulsifying agents. These emulsifying agents are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00075] Further, the concentrated composition of the invention optionally can include suspending agents to increase viscosity. The suspending agents may include, but are not limited to, acasia, bentonite, carboxymethylcellulose, methycellulose, hydroxypropylcellulose, carbomer resins, colloidal silicon dioxide, sodium alginate, tragacanth, agar, alginic acid, attapulgite, bentonite, carrageenan, cellulose, microcrystalline cellulose, microcrystalline carboxymethylcellulose, dextrin, gelatin, guar gum, hydroxyethylcellulose, hydroxypropylmethyl-cellulose, magnesium aluminum silicate, pectin, polaxamer, polyethylene oxide, polyvinyl alcohol, povidone, propylene glycol alginate, xanthan gum, and veegum. These suspending agents are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00076] Further, the concentrated composition of the present invention optionally can include stiffening agents to increase viscosity. The stiffening agents may include, but are not limited to, hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat, paraffin, synthetic paraffin, stearyl alcohol, emulsifying wax, white wax, and yellow wax. These stiffening agents are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00077] Further, the concentrated composition of the present invention optionally can include any substance, which can increase or decrease the pH of the system added.
The pH modifiers can be either acidifying agents or alkalizing agents. The pH can be modified to any pH, which is deemed suitable. These pH modifiers may include but are not limited to, (acidifying agents) acetic acid, acetic acid glacial USP, citric acid, hydrochloric acid, fumaric acid, lactic acid, nitric acid, phosphoric acid, sodium phosphate monobasic, sulfuric acid, malic acid, tartaric acid propionic acid, (alkalizing agents) ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, sodium bicarbonate, sodium borate, sodium phosphate dibasic, trolamine, potassium hydroxide, sodium hydroxide, and sodium carbonate. These PH modifiers are not particularly limited;
any of those known in the pharmaceutical or cosmetic industries may be used.
[00078] Further, the concentrated composition of the present invention optionally can include any solubilizing agent. These agents may include but are not limited to, benzalkonium chloride, cetylpyridium chloride, benzethonium vz chloride, docusate sodium, nonoxynol 9, octoxynol 9, polaxamer(s), polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, and tyloxapol. These wetting and/or solubilizing agents are not particularly limited; any of those known in =the pharmaceutical or cosmetic industries may be used.
[00079] Further, the concentrated composition of the present invention optionally can include any substance, which can increase the shelf life of said product. These agents may include but are not limited to, vitamin E and ascorbic acid. These substances are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00080] In one embodiment, the concentrated hormone pharmaceutical composition contains 32 mg/g estriol, 4 mg/g estradiol, and 4 mg/g estrone concentrates (triest) in 960 mg/g of a mixture of 50% ethoxy diglyco1/50% propylene glycol. The estriol, estradiol, and estrone are present in the composition at 8:1:1, 6:3:1, 5:4:1 or 7:2:1 ratios.
[00081] After extensive research, the present inventor discovered that the combination of ethoxy diglycol and propylene glycol in any ratio has the ability to dissolve the combination of estriol, estradiol, and estrone (triest) in any ratio or testosterone alone better than using any of the solvents alone.
[00082] In another embodiment, the concentrated hormone pharmaceutical composition contains 32 mg/g estriol and 8 mg/g estradiol concentrates (biest) in 960 mg/g of a mixture of 50% ethoxy diglyco1/50% propylene glycol. The estriol and estradiol are present in the composition at 8:2, 5:5, 6:4, 7:3, or 9:1 ratio.
[00083] In another embodiment, the concentrated hormone pharmaceutical composition contains 64 mg/g testosterone concentrate in a mixture of 50% ethoxy diglyco1/50%
propylene glycol for women and 150 mg/g of a mixture of 50%
ethoxy diglyco1/50% propylene glycol for men.
[00084] In another embodiment, the concentrated hormone pharmaceutical composition contains 600 mg/g of progesterone concentrate in vanishing cream type oil in water emulsion base.
[00om] In another embodiment, the concentrated hormone pharmaceutical composition contains 0.8 g/g estriol, 0.1 g/g estradiol, and 0.1 g/g estrone (triest) in a powdered form optionally mixed with any amount of a filler or in the following ratios: 8:1:1, 7:2:1, 6:3:1, or 5:4:1.
[00086] In another preferred embodiment, the concentrated hormone pharmaceutical composition contains 0.8 g/g estriol and 0.2 g/g estradiol (biest) in a powdered form optionally mixed with any amount of a filler or in the following ratios: 5:5, 6:4, 7:3, 8:2, or 9:1.
[00087] In another preferred embodiment, the concentrated hormone pharmaceutical composition comprises:
at least one hormone;
optionally a powdered base;
wherein the at least one hormone is chosen from estriol, estradiol, or combination thereof; and wherein the composition is in a powdered form.
gmom The at least one hormone a combination of estriol, estradiol in a ratio of 5:5, 6:4, 7:3, 8:2, or 9:1.
[00089] In another preferred embodiment, the concentrated hormone pharmaceutical composition comprising:
at least one hormone; and optionally a powdered base;
wherein the at least one hormone is chosen from estriol, estradiol, estrone, or combination thereof; and wherein the composition is in a powdered form.
[0*090] The at least one hormone is a combination of estriol, estradiol, and estrone in a ratio of 5:4:1, 6:3:1, 7:2:1, or 8:1:1.
[00091] Examples of powdered bases suitable for use in the pharmaceutical compositions disclosed herein include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
glom In another embodiment of the present invention, the at least one hormone is combined directly with the pharmaceutically acceptable carrier (ointment, cream, powder or gel base) without the prior use of a solvent or solvents.
[00093] In a further embodiment of the present invention, the hormone is weighed and packaged unadulterated in an appropriate container. The solvent or solvents and/or optionally the ointment, cream, gel base, or powdered base are packaged in a separate container. The two products are sold together as a kit. The two components are to be combined by whoever purchases the kit to formulate the hormone concentrate system.
[00094] Color coded-concentrated pharmaceutical composition [00095] The present invention also provides a color-coded concentrated hormone composition to help the pharmacist quickly choose the composition to be used.
[00096] The advantage of having color-coded concentrates are as follows:
helps to rapidly identify the concentrate.
ensures that all concentrates required to be contained in a final product are present in said final product. This is made possible because each combination and permutation of the concentrates will result in a distinct color profile. If the final product does not match the color profile for that medication, you know you have done something wrong; and ensures complete mixing of the final product. When the final product is a uniform color throughout, adequate mixing will have taken place.
[00097] The coloring agent could possibly be, but is not limited to one of the following: acid red 52, basic fuchsin USP, brilliant green, caramel NF, carmine NO.40, congo red, D&C green NO.5, D&C green NO.6, D&C green NO. 8, D&C orange NO.4, D&C red NO.4, D&C red NO.6, D&C red NO.17, D&C red NO.
22, D&C red NO.28, D&C red NO.33, D&C violet NO.2, D&C
yellow NO.8, D&C yellow NO.10, D&C yellow NO.11, F.D. &C.
blue NO.1, F.D. &C. blue NO.2, F.D. &C. green NO.3, F.D. &C.
red NO.3, F.D. &C. red NO.19, F.D. &C. red NO.40, F.D. &C.
yellow NO.5, F.D. &C. yellow NO.6, malachite green oxalate, rose Bengal, saffron, scarlet red, and any food color in liquid or powder form. The coloring agent is not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be employed.
Preferably, the coloring agent will not noticeably color the skin. It should be compatible with the skin with the least number of adverse effects.
[00098] The concentrates according to the present invention would be manufactured using extensive safety measures. These include, but are not limited to, the use of custom built clean rooms (a room designed specifically for compounding with hazardous materials), high velocity air flow units fitted with high emission particulate air (HEPA) filters, custom built ventilation systems, protective suits, protective eyewear, protective gloves, and protective HEPA
filter masks.
[00099] A pharmacist or technician trained in the art of compounding BHRT ointments, creams, gels, and pastes will manufacture these concentrates.
gmolom An advantage of the present invention is the composition contains a high concentration of hormones (higher than the prescribed levels), thus the pharmacist can easily use the concentrates to produce a custom tailored BHRT product without risking his own health.
[000101] The present invention also contemplates a method for producing the concentrated composition of the present invention. The method comprises the steps of:
measuring at least one hormone, a solvent and/or optionally a carrier by using an electronic balance in a clean room;
combining the ingredients of step a by using an industrial scale mixer to ensure thorough mixing; and running the mixture of step b through a large-scale ointment mill or homogenizer to decrease the particle size of the drug, and optionally, heating the concentrate to facilitate the formation of a solution, wherein the hormone concentration is from about 0.6 to about 80%.
[000102] The concentrated hormone pharmaceutical composition of the present invention may be further divided with similar or different carrier materials to concentrations that are suitable for practical use by the compounding pharmacist.
[000103] If the medication is not thoroughly mixed, then it will not contain a uniform concentration of the drug throughout. A solution will provide the best distribution of drug throughout the system.
[000104] Running the mixture through a large-scale ointment mill or using a homogenizer decreases the particle size and increases the absorbability, because smaller drug particles will more readily penetrate the dermis. This process also ensures a non-gritty, pharmaceutically elegant, and cosmetically pleasing final product.
[00010] The present invention is also in combination with a dispensing device to provide a means to measure and combine, quickly and accurately, quantities of hormones with appropriate ointment, cream, or gel bases while minimizing exposure to hazardous airborne hormone particles. Thus, airborne particles are drastically reduced because the hormones are incorporated into a liquid or semi-solid form.
Example 1 [000106] The formulation was made in the following manner (total quantity: 120 ml and a concentration of 300mg/g of testosterone) 36g of testosterone were weighed out.
b) the volume was brought up to 120m1 with approximately 84 ml of an anhydrous gel base.
1 drop of blue food coloring was added.
the mixture was combined in an electronic mortar and pestle.
the mixture was run through an ointment mill to decrease the particle size of the testosterone.
the mixture was transferred into 4 30m1 luer lock syringes.
This is what the mixture is sold in.
Example 2 [000107] The formulation, according to the invention, was made in the following manner (total quantity: 1000m1 and a concentration of 62.5mg/g of triest (estriol, estradiol, and estrone in an 8:1:1 ratio) 50g of estriol were weighed out and wetted with 50m1 of ethoxy diglycol.
6.25g of estradiol were weighed out and wetted with 6.25m1 of ethoxy diglycol.
6.25g of estrone were weighed out and wetted with 6.25m1 of ethoxy diglycol.
drops of red food coloring was added.
the volume was brought up to 1000m1 with approximately 875m1 of oil in water emulsion type vanishing cream base.
the mixture was combined in an industrial mixer.
the mixture was run through an ointment mill to decrease the particle size of the estrogens.
the mixture was transferred into 33 30m1 luer lock syringes.
This is what the mixture is sold in.
=
Example 3 MOM] The formulation, according to the invention, was made in the following manner (total quantity: 5000 ml and a concentration of 400mg/g of progesterone) 2000g of progesterone were weighed out.
the progesterone was combined with an oil phase, an aqueous phase and an emulsifier to formulate a water in oil emulsion type cream base with a final volume (including the progesterone) of 5000m1.
50 drops of yellow food coloring was added.
the mixture was combined in an industrial mixer.
the mixture was run through an ointment mill to decrease the particle size of the progesterone.
the mixture was transferred into 83 60m1 luer lock syringes.
This is what the mixture is sold in.
Example 4 [000109] The formulation, according to the invention, was made in the following manner (total quantity: 10000 ml and a concentration of 600mg/g of progesterone (this is a paste) 6000g of progesterone were weighed out.
the progesterone was combined with 2000m1 of ethoxy diglycol.
100 drops of yellow food coloring was added.
an oil in water emulsion type vanishing cream base was used to bring the final volume to 10000m1, approximately 2900g of the cream.
the mixture was combined in an industrial mixer.
the mixture was run through an ointment mill to decrease the particle size of the progesterone.
the mixture was transferred into 50m1 ointment jar. This is what the mixture is sold in.
Example 5 [000110] The formulation, according to the invention, was made in the following manner (total quantity: 2000 ml and a concentration of 300mg/g of testosterone) 600g of testosterone were weighed out.
The testosterone was combined with approximately 400m1 of ethoxy diglycol.
15 drops of blue food coloring was added.
Approximately 1000m1 of a 1% hydroxypropylcellulose in ethoxy diglycol anhydrous gel was added to bring the final volume to 2000m1.
The mixture was combined in an industrial mixer.
The mixture was further mixed with a homogenizer to decrease the particle size of the testosterone.
The mixture was transferred to 40 50m1 bottles fitted with adapter caps. A 5m1 oral syringe and a lml oral syringe, fitting the adapter cap, were packaged with each bottle to be used as measuring devices.
Example 6 [000111] The formulation, according to the invention, was made in the following manner (total quantity: 10000m1 and a concentration of 40 mg/g of triest (estriol, estradiol, and estrone in an 8:1:1 ratio)) 320g of estriol were weighed out.
40g of estradiol were weighed out.
40g of estrone were weighed out.
100 drops of red food coloring was added.
The volume was brought up to 10000m1 with a 50% ethoxy diglycol and 50% propylene glycol combination.
The mixture was combined in an industrial mixer.
The mixture was heated to 60 degrees Celsius for 2 hours in order to facilitate solution of the triest powder.
The solution was transferred into 100 100m1 bottles fitted with adapter caps, accompanied with lml, 5m1, and 10m1 oral syringes. This is what the mixture is sold in.
Example 7 MOM The formulation, according to the invention, was made in the following manner (total quantity: 2000 ml and a concentration of 70mg/g of testosterone) 140g of testosterone were weighed out.
15 drops of blue food coloring was added.
The testosterone was combined with approximately 1860m1 of ethoxy diglycol, enough to bring the final volume to 2000m1.
The mixture was combined in an industrial mixer.
The mixture will now be a solution.
The solution was transferred to 40 50m1 bottles fitted with adapter caps. A 5m1 oral syringe and a lml oral syringe, fitting the adapter cap, were packaged with each bottle to be used as measuring devices.
Example 8 [00OW] The formulation, according to the invention, was made in the following manner (total quantity: 2000 ml and a concentration of 150mg/g of testosterone) 300g of testosterone were weighed out.
15 drops of blue food coloring was added.
The testosterone was combined with approximately 1700m1 of a 50% ethoxy diglycol and 50% propylene glycol mixture, enough to bring the final volume to 2000m1.
The mixture was heated to 60 degrees Celsius and mixed in an industrial mixer.
The mixture will now be a solution.
The solution was transferred to 40 50m1 bottles fitted with adapter caps. A 5m1 oral syringe and a lml oral syringe, fitting the adapter cap, were packaged with each bottle to be used as measuring devices.
[000114] Example 9 mom] The formulation, according to the invention, was made in the following manner (total quantity: 1000gm and a - _ concentration of 62.5mg/gm of triest (estriol, estradiol, and estrone in an 8:1:1 ratio)) 50g of estriol were weighed.
6.25g of estradiol were weighed out.
6.25g of estrone were weighed out.
The weight was brought up to 1000gm with approximately 937.5gm of lactose.
The mixture was combined in an industrial mixer.
The mixture was transferred to 10 100gm jars.
[000116] Example 10 [000117] The formulation, according to the invention, was made in the following manner (total quantity: 1000m1 and a concentration of 40mg/g of triest (estriol, estradiol, and estrone in an 8:1:1 ratio)) 32g of estriol were weighed out.
4g of estradiol were weighed out.
4g of estrone were weighed out.
The three powders were combined.
4g of this combination were transferred into each of 10 100m1 bottles fitted with adapter caps.
Approximately 96m1, enough to bring the final volume to 100m1, of a 50% ethoxy diglycol and 50% propylene glycol mixture was transferred to each of 10 other 100m1 bottles fitted with adapter caps.
The bottles could be sold as a kit or as 2 separate entities. 1 bottle of powder and 1 bottle of solvent would constitute 1 kit. The purchaser would add the solvent to the bottle containing the powder using an oral syringe so as not to be exposed to the powdered hormones. With stirring, at 50 degrees Celsius, the combination would form a solution. This solution is the hormone concentrate.
Example 11 [000118] The formulation, according to the invention, was made in the following manner (total quantity: 100m1 and a -concentration of 40mg/g of triest (estriol, estradiol, and estrone in an 8:1:1 ratio)) 3.2g of estriol were weighed out and transferred into a 100m1 bottle.
0.4g of estradiol were weighed out and transferred into a 100m1 bottle.
0.4g of estrone were weighed out and transferred into a 100m1 bottle.
Enough colored 50% propylene glycol/50% ethoxy diglycol mixture to combine with the estriol, estradiol, and estrone to bring the final volume to 100m1, approximately 96m1, was measured and transferred into a 100m1 bottle.
Example 12 [000119] The formulation, according to the invention, was made in the following manner (total quantity: 120 ml and a concentration of 300mg/g of testosterone) 36g of testosterone were weighed out.
The volume was brought up to 120m1 with approximately 84 ml of a glycerin.
1 drop of blue food coloring was added.
The mixture was combined in an electronic mortar and pestle.
The mixture was run through an ointment mill to decrease the particle size of the testosterone.
The mixture was transferred into 4 30m1 luer lock syringes. This is what the mixture is sold in.
[000120] The mixture of example 11 will be sold as a kit in which the pharmacist will combine the elements to produce the hormone concentrate system. The pharmacist will transfer the liquid into the bottle containing the estriol, then transfer this mixture into the bottle containing the estradiol, then transfer this mixture into the bottle containing the estrone. This final solution will be the triest concentrate.
[000121] These concentrates could be packaged in, or with, any graduated dispensing device that lends itself to accurately measure specific volumes of liquids or semi-solids including, but not limited to, a metered dose tube, a metered dose pump, a metered dose syringe, a bottle, an ointment jar, a metered dose spray bottle, a bottle fitted with an adapter cap, and a luer lock syringe, a pipette, a bottle top dispenser, a burette, and a metered dose scoop.
The packaging, dispensing, or measuring devices are not particularly limited. Any of those known in the pharmaceutical, chemical, or cosmetic industries may be used.
[000122] A specific amount, different for each compound, of these concentrates would be combined with an appropriate amount of any ointment, cream, or gel base, suitable for transdermal administration of bio-identical hormones, to form a final product which contains the doctor prescribed concentration of each bio-identical hormone.
[000123] The pharmacist using the concentrate, according to the invention, can easily incorporate the hormone into the compounding BERT ointments, creams, gels, or pastes by:
Putting on protective gloves.
Calculating the total amount of hormones needed to compound a medication of a specific volume and concentration depending on the patient necessities;
Determining how many milliliters of the appropriate concentrate will contain the total amount of hormone needed for the compound.
Measuring the volume of concentrate containing the total amount of hormone needed. This is done using an appropriate liquid or semi-solid measurement system.
Repeating steps 2 through 4 for each hormone to be present in the final preparation.
Calculating the amount of the appropriate ointment, cream, or gel base, which is needed for the final product.
This is accomplished by subtracting the total volume of concentrates used from the total volume needed.
Combining the ointment, cream, or gel base and the concentrates on a glass ointment slab, using an EMP, mixing them an appropriate number of times between two luer lock syringes attached together using a luer lock to luer lock adapter or any other form of mixing. When the color is uniform throughout, adequate mixing has taken place.
1000124] In another embodiment, the pharmaceutically acceptable carrier is sold inside a metered dose device.
These will make unnecessary to use a scale in measuring and making BHRT creams. This is a distinct advantage for pharmacies not presently engaged in the art of compounding.
The only additional equipment needed is a spatula for mixing. If the carrier is not packaged in a metered device, then the cream would have to be weighed and measured using a scale, which takes more time as well as additional cost to purchase the scale.
gam In addition, the invention concerns a kit for producing a concentrated hormone pharmaceutical composition, the kit comprising:
at least one hormone;
at least one solvent, and optionally a pharmaceutically acceptable carrier, wherein each element is packet in separated graduated dispensing devices.
[000126] In a further embodiment, the kit of the present invention comprises separately packing the at least one hormone and the at least one solvent in a container having internal divisions, wherein the at least one hormone and the at least one solvent are combined by the purchaser to form the hormone concentrate system.
[000127] Advantages [000128] The concentrated composition of the invention offers numerous advantages over compounding BHRT ointments, creams, gels, or pastes using a traditional method with commercially available hormones in powder form.
[WM Using these concentrates, combined with an appropriate liquid or semi-solid measurement system, in the place of powdered hormones and a scale, will dramatically reduce the risk of exposure to hazardous airborne hormone particles. This is due to the fact that the powdered hormones are incorporated into a liquid or semi-solid. This means that the need for inconvenient, expensive, and time-consuming safety measures is greatly reduced. Since there are relatively few airborne particles, there is little or no need for the use of custom built clean rooms (a room designed specifically for compounding with hazardous materials), high velocity air flow units fitted with HEPA
filters, custom built ventilation systems, protective suits, protective eyewear, or protective HEPA filter masks. The only safety measure definitely required is protective gloves.
[000130] When the concentrates are manufactured, they are mixed using an industrial mixer, which ensures thorough mixing. This alleviates the need for purchasing and using an EMP for compounding BHRT ointments, creams, gels, or pastes.
They are also run through a large ointment mill or homogenizer to reduce the particle size of the drug. This will increase absorbability, as smaller drug particles will more readily penetrate the dermis. This process also ensures a non-gritty, pharmaceutically elegant, and cosmetically pleasing product. This alleviates the need for purchasing and using an ointment mill for compounding BHRT ointments, creams, gels, or pastes.
[000131] The concentrates of the present invention offer the advantage that they are easier and most accurate to measure. The fact that the hormones are in solution results in a superior final product, the product produced from the concentrates and dispensed to the patient. This is due to the fact that there are no particles. All particles have been solubilized. This results in a pharmaceutically elegant and easily penetrateable final product.
[000132] The fact that the concentrates are color-coded will greatly reduce the chance of compounding errors. The color system should reduce the inadvertent use of one hormone concentrate instead of another. It will also ensure that all of the intended concentrates are present in the final product. This is accomplished because each combination and permutation of the concentrates will have a distinct color profile. If the final product does not match its profile, then you know something has been done incorrectly.
The color system will also help ensure that the final product is uniformly mixed. When the final product is a consistent color throughout, you will have adequate mixing.
At the present time, most compounding pharmacists do not have an adequate system in place to ensure proper mixing.
Without proper mixing, the final product will not have a uniform concentration of the hormones throughout the system.
Since the concentrate system alleviates the need for most of the safety measures required for compounding these medications, as well as the need for a scale, EMP, and ointment mill, it significantly reduces the cost of compounding these medications. The concentrate system also significantly decreases the time needed to compound them.
This is because the number of steps needed to compound them is drastically reduced. This increase in efficiency will result in a proportional decrease in labor costs.
[0001341 The hormone concentrates and an appropriate liquid or semi-solid measurement system will make it possible for any pharmacist in any setting to safely and accurately compound BHRT ointments, creams, gels, and pastes. At the present time, only compounding pharmacists with elaborate compounding facilities and the proper equipment can compound them safely and accurately. Using this invention, any pharmacist in any setting will now be able to safely, quickly, inexpensively, and accurately compound BERT
ointments, creams, gels, and pastes. This will inevitably result in an increase in the availability of these medications to the public.
[0001351 The fact that each final product, the product dispensed to the patient, has a distinct colour profile has an additional benefit. It will help decrease the chance of dispensing the wrong product to a patient. If a patient was to receive a Tri-est cream (which should be pink) but a blue cream was labeled Tri-Est, the pharmacist would be easily able to identify the error. Also, the patient would be able to tell that their previous cream was pink and this one is blue, bringing this to the pharmacist's attention. At present time all hormone creams are white, making it all but impossible to detect, a labeling error. The colour coding also decreases the likely hood of choosing the wrong cream from the stock as each cream is readily identifiable. The coloring system allows each final product to be differentiated from one another.
{0006]A BHRT ointment, cream, gel, or paste may include, but is not limited to, the active hormone or hormones, a suitable solvent or solvents, including, but not limited to, ethoxy diglycol, propylene glycol, alcohol, or glycerin and any suitable ointment, cream, or gel base which allows for transdermal absorption of bio-identical hormones.
[0007]Producing BHRT pharmaceutical compositions is a very lucrative business for compounding pharmacies. However, the process of producing the BHRT pharmaceutical compositions is an extremely time-consuming process and has many risks and subsequent costs associated with the compounding of BHRT
pharmaceutical compositions.
[0008]One of the main problems with compounding BHRT
pharmaceutical compositions is the substantial risk of employee contamination (inhalation or transdermal absorption of the hormones) with the hormones. The hormones used for producing the BHRT pharmaceutical compositions are naturally found in the body in physiological levels. Thus, when a human is chronically exposed to higher than normal levels of these hormones, they are at risk of developing serious adverse medical effects, including, but not limited to, an unnatural increased response by each system of the body which is affected by each individual hormone, as well as an increased risk of developing numerous varieties of cancer.
[0009] In addition, producing these BHRT pharmaceutical compositions requires great skill and knowledge. It also requires expensive equipment such as accurate electronic scales, electronic mortars and pestles (EMP), and ointment mills.
[00010] In order to diminish these risks, the compounding pharmacies have developed an expensive and time-consuming method to reduce employee exposure to these hormones. These measures include, but are not limited to, the use of a custom built clean room, high velocity air flow units fitted with high emission particulate air (HEPA) filters, custom built ventilation systems, protective suits, protective eyewear, protective gloves, and protective HEPA filter masks.
[00011] The production of BHRT pharmaceutical compositions is by itself a time-consuming process. Each ointment, cream, gel, or paste must be specifically engineered for each patient based on his or her distinct hormone profile, thus the use of bulk compounding is precluded, because each medication is produced custom fit for each patient.
[00012] Furthermore, bulk compounding or manufacturing of hormone products is illegal in most states without a proper license.
[00013] In order to produce these BHRT pharmaceutical compositions safely and accurately, compounding pharmacies need to invest a great deal of time and money into these safety measures. The pharmacies would also need to employ a specially trained staff; all these measures decrease productivity substantially.
[00014] These measures are not only expensive, but also create an unpleasant work environment. This is due to the fact that the employee is covered from head to toe in restrictive, uncomfortable protective gear. They are also working in a room, which is noisy because of the high velocity ventilation systems, which are in constant use.
[00015] In order to work with BHRT pharmaceutical compositions, an employee must:
Be trained in the art of compounding BHRT ointments, creams, gels, and pastes.
Ensure they are wearing all the necessary protective gear.
Locate all of the ingredients.
Weigh all of the ingredients in the appropriate environment, a clean room with proper ventilation and filtration systems, to prevent exposure to harmful chemicals.
Combine the ingredients using the EMP to ensure thorough mixing. If the mixture is not thoroughly mixed, then it will not contain a uniform concentration of the drug throughout.
Run the mixture through an ointment mill to decrease the particle size of the drug. This will increase absorbability, as smaller drug particles will more readily penetrate the dermis. This process also ensures a non-gritty, pharmaceutically elegant, and cosmetically pleasing final product.
[00016] The combination of the potential risks associated with producing BHRT pharmaceutical compositions, specially trained employees to compound these compositions safely and accurately, purchasing all the necessary equipment and safety measures, and the actual time required to compound each individual pharmaceutical composition result in an .extremely time-consuming, hazardous, and expensive process.
[00017] The present inventor thought of the necessity of providing pharmacies with a system that is easy to use and saves time and money for those pharmacies dealing with BHRT
pharmaceutical products while decreasing risk and increasing product quality.
SUNMARY OF THE INVENTION
[00018] The invention offers at least one of the following advantages:
provides a concentrated pharmaceutical composition that is easy to use and saves time and money to the pharmacies dealing with BHRT pharmaceutical products.
provides a pharmaceutical composition having a higher concentration of hormone than the concentration found in the BHRT pharmaceutical products of the prior art.
provides a pharmaceutical composition that can be used by the compounding pharmacist safely, accurately, quickly.
provides an inexpensive pharmaceutical composition with individualized BHRT products such as ointments, creams, gels, or pastes.
provides a color-coded hormone pharmaceutical composition.
[00019] The concentrated composition of the present invention can be manufactured to contain a higher concentration of hormone (or combination of hormones) than the standard concentration of hormones prescribed by physicians, thus the pharmacist can easily measure the amount required to be incorporated into the EHRT product.
[00020] The concentrated composition of the present invention could include any concentration of any hormone or any combination of hormones in any proportion as long as the concentration is greater than the accepted physician prescribed concentrations to treat hormone deficiencies.
[00021] The present invention also relates to a metered dispensing device including the composition of the invention to provide a means to measure and combine, quickly and accurately, quantities of hormones with appropriate ointment, cream, or gel bases by the compounding pharmacist while minimizing exposure to hazardous airborne hormone particles. Thus, airborne particles are drastically reduced because the hormones are incorporated into a liquid or semi-solid form.
[00022] The present invention relates to a concentrated hormone Pharmaceutical composition comprising:
from about 0.6 to about 80% of at least one hormone;
from about 20 to about 90.4 % of at least one solvent, and optionally a pharmaceutically acceptable carrier.
[00023] In the preferred embodiment, the concentrated hormone pharmaceutical composition is chosen from estradiol, estrone, estriol, testosterone, DHEA, pregnenolone, progesterone, or combination thereof.
[00024] The invention also relates to a concentrated hormone pharmaceutical composition comprising:
from about 0.6 to about 50% of at least one hormone;
from about 50 to about 90.4 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is chosen from estriol, estradiol, or combination thereof.
[00025] The at least one hormone is a combination of estriol and estradiol in a ratio of 5:5, 6:4, 7:3, 8:2, or 9:1.
[00026] Furthermore, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.6 to about 50% of at least one hormone;
from about 50 to about 90.4 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is chosen from estriol, estradiol, estrone, or combination thereof.
[00027] The at least one hormone is a combination of estriol, estradiol, and estrone in a ratio of 5:4:1, 6:3:1, 7:2:1, or 8:1:1.
[00028] Furthermore, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.8 to about 80% of at least one hormone;
from about 20 to about 90.2 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is testosterone.
[00029] In addition, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 8 to about 90% of at least one hormone;
from about 10 to about 92 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is progesterone.
[00030] Furthermore, the invention concerns to a color-coded concentrated hormone pharmaceutical.
[00031] Furthermore, the invention concerns a method for producing a concentrated hormone pharmaceutical composition, the method comprising the steps of:
measuring at least one hormone, a solvent and/or optionally a carrier by using an electronic balance in a clean room;
combining the ingredients of step a by using an industrial scale mixer to ensure thorough mixing; and running the mixture of step b through a large-scale ointment mill or homogenizer to decrease the particle size of the drug, and optionally, heating the concentrate to facilitate the formation of a solution, wherein the hormone concentration is from about 0.6 to about 80%.
WOOM Furthermore, the present invention concerns a concentrated hormone pharmaceutical composition comprising:
at least one hormone;
optionally a powdered base;
wherein the at least one hormone is chosen from estriol, estradiol, estrone, or combination thereof; and wherein the composition is in a powdered form.
[00033] Finally, the invention concerns a kit for producing a liquid or semi-solid concentrated hormone pharmaceutical composition, the kit comprising:
at least one hormone;
at least one solvent, and optionally a pharmaceutically acceptable carrier, wherein each element is packet in separated graduated dispensing devices.
[00034] The foregoing has outlined rather broadly the more pertinent and important features of the present invention in order that the detailed description of the invention that follows may be better understood, and so that the present contribution to the art can be more fully appreciated.
Additional features of the invention that will be described hereinafter form the subject matter of the claims of the invention. It should be appreciated by those skilled in the art that the conception and the specific embodiments disclosed might be readily utilized as a basis for modifying or formulating other liquid formulations for carrying the same purposes of the present invention. It should also be realized by those skilled in the art that such equivalent formulations do not depart from the spirit and scope of the invention as set forth in the appended claims.
DETAILED DESCRIPTION OF THE INVENTION
[00035] The present invention concerns a pharmaceutical composition, including high concentrations of hormone that can be used by the compounding pharmacist safely, accurately, quickly, and inexpensively to produce individualized BHRT products such as ointments, creams, gels, or pastes.
[00036] The present invention concerns a concentrated hormone pharmaceutical composition comprising:
at least one hormone;
at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the weight concentration of the at least one hormone in said composition is equal or greater than 0.6%.
[00037] In one of the embodiments, the concentrated is in a powdered form.
[00038] The term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
Hormones [00039] The present invention contemplates the use of any one of the steroid hormones derived from cholesterol including, but not limited to, estrogen (estriol, estradiol, or estrone), progesterone, testosterone, dehydroepiandrosterone, norethisterone acetate, norgestrel, levonorgestrel gestodene CPA chlormadinone acetate, drospirorenone, and 3-ketodesogestrel.
[00040] The concentrates also could include, but not be limited to, an estriol concentrate, an estradiol concentrate, an estrone concentrate, a combination estriol, estradiol, and estrone (triest) concentrate in any proportion, preferably in a 8:1:1, 5:4:1, 6:3:1, or 7:2:1 ratio; a combination of estriol and estradiol concentrate (blest) in any proportion, preferably in a 5:5, 6:4, 7:3, CA 02459869 2004-05-18 , 8:2, or 9:1 ratio; a combination estriol and estrone concentrate, a combination estradiol and estrone concentrate, a progesterone concentrate, a combination progesterone and estriol concentrate, a combination progesterone and estradiol concentrate, a combination progesterone and estrone concentrate, a combination progesterone and triest concentrate, a combination progesterone, estriol, and estradiol concentrate, a combination progesterone, estriol, and estrone concentrate, a combination progesterone estradiol, and estrone concentrate, any of the previously mentioned concentrates in combination with testosterone i.e. a combination triest, progesterone, and testosterone concentrate, a testosterone concentrate, any of the previously mentioned concentrates in combination with dehydroepiandrosterone (DHEA), and a DHEA
concentrate.
[00041] In addition, any of the sex hormones may be used.
Any androgen including, but not limited to, testosterone may be used. Any progestogen including, but not limited to, progesterone may be used. Any estrogen including, but not limited to, estriol, estradiol, or estrone may be used.
[00042] The concentrated composition of the present invention could include any concentration of any hormone or any combination of hormones in any proportion as long as the concentration is greater than the accepted physician prescribed concentrations to treat hormone deficiencies.
[00043] The present invention provides a concentrated pharmaceutical composition that contains any ratio of estriol to estradiol (biest) having between 6 mg/g and 900 mg/g of biest, preferably between 8 mg/g and 200 mg/g, even more preferably 10mg/g to 60 mg/g.
[00644] In addition, the present invention provides a concentrated pharmaceutical composition that contains any ratio of estriol, estradiol, and estrone (triest) having between 6 mg/g and 900 mg/g of the triest, preferably between 8 mg/g and 200 mg/g, even more preferably 10 mg/g and 60 mg/g.
[00045] Furthermore, the present invention provides a concentrated pharmaceutical composition that contains between 10 mg/g and 900 mg/g of estriol, preferably between 15 mg/g and 300 mg/g, even more preferably 15 and 60 mg/g.
[00046] The present invention provides a concentrated pharmaceutical composition that contains between 1 mg/g and 900 mg/g of estradiol, preferably between 1.5 mg/g and 100 mg/g.
[00047] The present invention also provides a concentrated pharmaceutical composition that contains between 1 mg/g and 900 mg/g of estrone, preferably between 1.5 mg/g and 100 mg/g.
[00048] In addition, the present invention provides a concentrated pharmaceutical composition that contains between 10 mg/g and 800 mg/g of testosterone, preferably between 15 mg/g and 900 mg/g, even more preferably between 15 mg/g and 300 mg/g, for use in a female BHRT product.
[00049] Furthermore, the present invention provides a concentrated pharmaceutical compound that contains between 100 mg/g and 900 mg/g of testosterone, for use in a male BHRT product.
[00050] In addition, the present invention provides a concentrated pharmaceutical compound that contains between 200 mg/g and 900 mg/g of progesterone, more preferably between 400 mg/g and 800 mg/g, even more preferably 600mg/g.
[00051] Furthermore, the present invention provides a concentrated pharmaceutical compound that contains between mg/g and 900 mg/g of dehydroepiandrosterone or between 30 mg/g to 800 mg/g of pregnenolone.
[00052] The invention also concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.6 to about 50% of at least one hormone;
from about 50 to about 90.4 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is chosen from estriol, estradiol, or combination thereof.
[00053] In addition, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.6 to about 50% of at least one hormone;
and from about 50 to about 90.4 % of at least one solvent, optionally a pharmaceutically acceptable carrier wherein the at least one hormone is chosen from estriol, estradiol, estrone, or combination thereof.
[00054] Furthermore, the invention concerns a concentrated hormone pharmaceutical composition comprising:
from about 0.8 to about 80% of at least one hormone;
from about 20 to about 90.2 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is testosterone.
R0059 The invention also concerns a concentrated hormone pharmaceutical composition comprising:
from about 8 to about 90% of at least one hormone;
from about 10 to about 92 % of at least one solvent, and optionally a pharmaceutically acceptable carrier wherein the at least one hormone is progesterone.
Solvent (or Wetting agent) [00056] The solvent or wetting agent can be any liquid that can dissolve, partially dissolve, wet, or suspend the hormone, or reduce the surface tension of a liquid to a value below the hormones critical surface tension.
[00057] In order for a solid to be incorporated into a liquid, the solids surface tension must be above the surface tension of the liquid. The best solvents produce a low air liquid surface tension, and are not readily adsorbed by the solid so as to produce nonwetting behavior.
ROOM The wetting agent or solvent acts by lowering the contact angle between the surface of the particle and the wetting liquid. Wetting agents replace a solid to air interface with a solid to liquid interface. The solvent or wetting agent should be miscible with the carrier.
[00059] The solvent or wetting agent could possibly be, but is not limited to, one or more of the following in any concentration: propylene glycol, ethoxy diglycol, glycerin, mineral oil, fixed oil, emu oil, peanut oil, vitamin E oil, acetone, amylene hydrate, benzyl benzoate, corn oil, cottonseed oil, diethylene glycol monoethyl ether, ethyl acetate, isopropyl alcohol, methyl alcohol, methylene chloride, methyl isobutyl ketone, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, sesame oil, alcohol, a 50% ethoxy diglycol (diethylene glycol mono-ehyletherand) 50% propylene glycol mixture, water or mixtures threrof. Any combination of solvents may be employed.
gmow The solvent or wetting agent should satisfy the following characteristics:
the solvent or solvents should wet the hormone;
the solvent should allow the hormone to be incorporated therein;
the solvent or solvents should be compatible with the skin with the least possible number of adverse effects;
the solvent or solvents should be smooth and pliable with no adverse odor;
the solvent or solvents should have a color appealing to the consumer; and the solvent must be stable and must provide a stable vehicle for the medication.
[00061] The scope of the present invention is not limited by the solvents mentioned in the present application; any of those known in the pharmaceutical and cosmetic industries may be employed.
Pharmaceutically acceptable Carrier [00062] The carrier can be any suitable carrier that can be incorporated into a system, which can deliver bio-identical hormones transdermaly.
[00063] The formulations for the delivery of the pharmaceutical composition according to the present invention may be liquid, ointments, and creams.
gmoGc The carrier can be chosen from ointment base, powder base, cream base, or a gel base.
[00065] Ointments are semisolid preparations, which are typically based on petrolatum or other petroleum derivatives. Creams containing the selected active agent, are, as known in the art, viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil.
[00066] Cream bases are water-washable, and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, also sometimes called the "internal" phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
[00067] The specific ointment or cream base to be used, as will be appreciated by those skilled in the art, is one that will provide for optimum drug delivery. As with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and non-sensitizing.
[00068] Powders may be formulated with the aid of any suitable powder base, such as talc, lactose, starch, and the like.
gmow The pharmaceutical carrier could possibly be comprised of, but is not limited to, any or all of the following ingredients: an oil in water emulsion base, a water in oil emulsion base, an oleaginous base, an absorption base, a water soluble base an anhydrous gel, a pluronic F127/lecithin isopropyl palmitate gel, hydrous gel, purified water, white petrolatum, cetearyl alcohol, ceteareth-20, sorbitol solution, propylene glycol, simethicone, glyceryl monostearate, polyethylene glycol monostearate, sorbic acid, camellia sinensis (green tea) leaf extract, cholesterol, beeswax, cyclomethicone, C 12-15 alkyl benzoate, plankton extract, acetyl ponta peptide-2, ocnethera biennis (evening primrose) root extract, dimethicone, hexyldecanol, dextran, stearyl alcohol, cetyl alcohol, pyrus malus (apple) fruit extract, acetyl hexapeptide-2, alnus firmirolia (yashabushi) extract, tocopheryl acetate (vitamin E acetate), glyceryl stearate, thioctic acid (a-lipoic acid), PEG-100 stearate, ascorbyl palmitate ( vitamin C palmitate), tocopherol (vitamin E), tetrahexyldecyl ascorbate, sesamum indicum (sesame) seed oil, retinyl palmitate (vitamin A palmitate), Prunus armeniaca (apricot) kernel oil, willow bark extract, phenoxyethanol, benzyl alcohol, potassium sorbate, glycerin, panthenol (pro-vitamin B5), retinal (vitamin A), lavandula agustifolia (lavender) oil, allantoin, polysorbate 20, xanthan gum, titanium dioxide, tetrasodium EDTA, topheryl linoleate (vitamin E linoleate), dimethylamino methylpropanol, ceramide 2, quaternium-15, polyacrylamide, magnesium aluminum silicate, laureth-7, citric acid, C13-14 isoparaf fin, aloe barbadensis (aloe vera) leaf juice, cetearyl glucoside, 10-hydroxydecanoic acid, hydroxycaprylic acid, prunus amygdalus dulcis (sweet almond)oil, zinc PCA, zinc oxide, acacia, tragacanth, agar, pectin, gelatin, methyl cellulose, carboxymethylcellulose, carbomer, vitis vinifera (grape) seed extract, hibiscus sabdariffa flower extract, triticum vulgare (wheat)germ oil, citic acid, sodium hydroxymethylglycinate, isopropyl palmitate, squalane, cetearyl glucoside, lecithin, pluronic, cucumis sativus (cucumber) fruit extract, cetyl ricinoleate, caprylic/capric triglycerides, allantoin, ubiquinone (coenzyme Q10), helianthus annuus (hybrid sunflower) oil, cyclomethicone sodium PCA, stearic acid, glyceryl stearate, rose canina (rose hips) fruit oil, glycol, glycyrrhiza glabra (licorice) extract,aesculus hippacastanum (horse chestnut)extract, hydrolyzed yeast protein, calendula off icinalis flower extract, centella asiatica (gotu kola) extract, ruscus aculeatus (butcher's broom)root extract, cyclopentasiloxane, evening primrose oil, PEG-75, PEG-150, sodium PCA, calendula officinalis flower extract, cyclopentasiloxane, hydrolyzed milk protein, ethoxy diglycol, lupinus albus seed oil, hydrophilic petrolatum, wool alcohol, sodium lauryl sulfate, PEG 4000, PEG 400, propylene glycol-ethanol, lecithin soya granular, sorbic acid, polyacrylamide, cytel alcohol, magnesium aluminum silicate, aloe vera (aloe barbadensis) prunus amygadalus amara (bitter almond) kenel oil, pro-lipo multi-emulsion liposomic system, propylparaben, methylparaben, imidazolidimyl urea, pluronic F127, alcohol, sodium hydroxide, DMAE, glycolic acid, edetate disodium dihydrate, urea, stearic acid, glyceryl monostearate, isopropyl myristate, polyoxyl 40 stearate, potassium sorbate, anhydrous ointment base, lanolin, anhydrous lanolin, emollient cream base, lanolin alcohol, mineral oil, glyceryl monostearate, stearic acid flakes, sualene, triethanolamine, krisgel 100, borago (borage) officinalis seed oil, simethicone, salicylic acid, dehydroacetic acid, benzyl alcohol, benzoic acid, benzethonium chloride, polysorbate 80, span, PEG-8 distearate/emerest 2712, hydrogenated vegetable oil, mineral oil (heavy), mineral oil (light), microethane FN 501, hydroxypropylcellulose, hydroxymethylcellulose, methylcellulose, avicel, polyglygol 300, polyglycol 8000, paraffin waxes, propylene glycol isostearate, isostearyl alcohol, white ointment USP, yellow ointment NF, oleic acid USP, olive oil USP, paraffin USP, petrolatum NF, spermaceti wax USP, synthetic spermaceti NF, starch glycerite NF, white wax USP, yellow wax USP, dbutylated hydroxy toluene, or combination thereof.
tamm The carrier should satisfy the following characteristics:
the base should allow the wetted hormone to be incorporated therein;
the base should be compatible with the skin with the least possible number of adverse effects;
the base should be smooth and pliable with no adverse odor;
the base should have a color appealing to the consumer;
the base must be stable and must provide a stable vehicle for the medication; and the base should be able to readily release the medication incorporated therein into the skin.
Additional Ingredients [00071] The concentrated pharmaceutical composition according to the invention optionally can include antioxidants to prevent oxidation of any of the components therein. The antioxidant may include, but are not limited to, ascorbic acid, sodium ascorbate, sodium formaldehyde sulfoxylate, sodium bisulfite, sodium nitrite, sodium thiosulfate, sodium metabisulfite, sodium sulfite, sulfur dioxide, tannic acid, thioglycerol, tert-butyl-hydroquinone, thioglycolic acid, thiolactic acid, thiosorbitol, thiourea, tocopherols, butylated hydroxy toluene, acetone sodium sulfate, acetylcysteine, lipoic acid (sodium salt), tocopherol, ascorbyl palmitate, butylated hydroxyanisole, calcium ascorbate, calcium bisulfite, calcium sulfite, . cysteine, dilauryl thiodipropionate, dithiothreitol,dodecyl gallate, ethoxyquin, ethyl gallate, gallic acid, glutathione, gossypol, hydroquinone,4-hydroxymethy1-2,6-di-tert-butylphenol, hypophosphorus acid, isoascorbic acid, lecithin, monothioglycerol, B-naphthol, nordihydroguaiaretic acid, octyl gallate, potassium metabisulfite, propyl gallate, sesamol, or Vitamin E. These antioxidants are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00072] In addition, the concentrated pharmaceutical composition according to the invention optionally may include preservatives to prevent the growth of bacteria or fungi in the final product. These may include, but are not limited to, thimerosal, benzyl alcohol, imidazolidinyl urea, quaternium-15, benzalkonium chloride, chlohexidine, chlorbutanol, phenol, cresol, chlorothymol, chloroxylenol, P-chlorometaxylenol, sodium benzoate, potassium sorbate, boric acid, methyl paraben, propylparaben, sorbic acid, alcohol, benzethonium chloride, benzoic acids and salts, benzyl alcohol, sodium benzoate, boric acids and salts, cetylpyridinium chloride, cetyltrimethyl ammonium bromide, chlorbutanol, clorocresol, imidazolidinyl urea, metacresol, myristylgamma picolinium chloride, nitromersol, parabens(benzyl, butyl, methyl, propyl), phenol, phenyl phenol, phenylethyl alcohol, phenylmercuric acetate/nitrate, sorbic acids and salts, thimerosal, hydroxybezoate esters and phenyl ethyl alcohol. These preservatives are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00073] Further, the concentrated composition of the invention optionally can include chelating agents and synergists added, which may include, but are not limited to, EDTA and salts, alkyl gallates, ascorbic acid, boric acid, citraconic acid, gluconic acid, hydroxyquinolone sulfate, maleic acid, phosphoric acid, polysorbates, saccharic acid, tartaric acid, tryptophan and citric acid. These chelating agents and synergists are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00074] Further, the concentrated composition of the invention optionally can include emulsifying agents to facilitate the formation of an emulsion. The emulsifying agents may include, but are not limited to acacia, tragacanth, agar, pectin, gelatin, methyl cellulose, carboxymethylcellulose, PEG-40 castor oil, PEG 300, polysorbate 20, polysorbate 40, polysorbate 80, sorbitan monopalmitate, simethicone, or any synthetic anionic, cationic, or nonionic emulsifying agents. These emulsifying agents are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00075] Further, the concentrated composition of the invention optionally can include suspending agents to increase viscosity. The suspending agents may include, but are not limited to, acasia, bentonite, carboxymethylcellulose, methycellulose, hydroxypropylcellulose, carbomer resins, colloidal silicon dioxide, sodium alginate, tragacanth, agar, alginic acid, attapulgite, bentonite, carrageenan, cellulose, microcrystalline cellulose, microcrystalline carboxymethylcellulose, dextrin, gelatin, guar gum, hydroxyethylcellulose, hydroxypropylmethyl-cellulose, magnesium aluminum silicate, pectin, polaxamer, polyethylene oxide, polyvinyl alcohol, povidone, propylene glycol alginate, xanthan gum, and veegum. These suspending agents are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00076] Further, the concentrated composition of the present invention optionally can include stiffening agents to increase viscosity. The stiffening agents may include, but are not limited to, hydrogenated castor oil, cetostearyl alcohol, cetyl alcohol, cetyl esters wax, hard fat, paraffin, synthetic paraffin, stearyl alcohol, emulsifying wax, white wax, and yellow wax. These stiffening agents are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00077] Further, the concentrated composition of the present invention optionally can include any substance, which can increase or decrease the pH of the system added.
The pH modifiers can be either acidifying agents or alkalizing agents. The pH can be modified to any pH, which is deemed suitable. These pH modifiers may include but are not limited to, (acidifying agents) acetic acid, acetic acid glacial USP, citric acid, hydrochloric acid, fumaric acid, lactic acid, nitric acid, phosphoric acid, sodium phosphate monobasic, sulfuric acid, malic acid, tartaric acid propionic acid, (alkalizing agents) ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, sodium bicarbonate, sodium borate, sodium phosphate dibasic, trolamine, potassium hydroxide, sodium hydroxide, and sodium carbonate. These PH modifiers are not particularly limited;
any of those known in the pharmaceutical or cosmetic industries may be used.
[00078] Further, the concentrated composition of the present invention optionally can include any solubilizing agent. These agents may include but are not limited to, benzalkonium chloride, cetylpyridium chloride, benzethonium vz chloride, docusate sodium, nonoxynol 9, octoxynol 9, polaxamer(s), polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 10 oleyl ether, polyoxyl 20 cetostearyl ether, polyoxyl 40 stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, sodium lauryl sulfate, sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate, sorbitan monostearate, and tyloxapol. These wetting and/or solubilizing agents are not particularly limited; any of those known in =the pharmaceutical or cosmetic industries may be used.
[00079] Further, the concentrated composition of the present invention optionally can include any substance, which can increase the shelf life of said product. These agents may include but are not limited to, vitamin E and ascorbic acid. These substances are not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be used.
[00080] In one embodiment, the concentrated hormone pharmaceutical composition contains 32 mg/g estriol, 4 mg/g estradiol, and 4 mg/g estrone concentrates (triest) in 960 mg/g of a mixture of 50% ethoxy diglyco1/50% propylene glycol. The estriol, estradiol, and estrone are present in the composition at 8:1:1, 6:3:1, 5:4:1 or 7:2:1 ratios.
[00081] After extensive research, the present inventor discovered that the combination of ethoxy diglycol and propylene glycol in any ratio has the ability to dissolve the combination of estriol, estradiol, and estrone (triest) in any ratio or testosterone alone better than using any of the solvents alone.
[00082] In another embodiment, the concentrated hormone pharmaceutical composition contains 32 mg/g estriol and 8 mg/g estradiol concentrates (biest) in 960 mg/g of a mixture of 50% ethoxy diglyco1/50% propylene glycol. The estriol and estradiol are present in the composition at 8:2, 5:5, 6:4, 7:3, or 9:1 ratio.
[00083] In another embodiment, the concentrated hormone pharmaceutical composition contains 64 mg/g testosterone concentrate in a mixture of 50% ethoxy diglyco1/50%
propylene glycol for women and 150 mg/g of a mixture of 50%
ethoxy diglyco1/50% propylene glycol for men.
[00084] In another embodiment, the concentrated hormone pharmaceutical composition contains 600 mg/g of progesterone concentrate in vanishing cream type oil in water emulsion base.
[00om] In another embodiment, the concentrated hormone pharmaceutical composition contains 0.8 g/g estriol, 0.1 g/g estradiol, and 0.1 g/g estrone (triest) in a powdered form optionally mixed with any amount of a filler or in the following ratios: 8:1:1, 7:2:1, 6:3:1, or 5:4:1.
[00086] In another preferred embodiment, the concentrated hormone pharmaceutical composition contains 0.8 g/g estriol and 0.2 g/g estradiol (biest) in a powdered form optionally mixed with any amount of a filler or in the following ratios: 5:5, 6:4, 7:3, 8:2, or 9:1.
[00087] In another preferred embodiment, the concentrated hormone pharmaceutical composition comprises:
at least one hormone;
optionally a powdered base;
wherein the at least one hormone is chosen from estriol, estradiol, or combination thereof; and wherein the composition is in a powdered form.
gmom The at least one hormone a combination of estriol, estradiol in a ratio of 5:5, 6:4, 7:3, 8:2, or 9:1.
[00089] In another preferred embodiment, the concentrated hormone pharmaceutical composition comprising:
at least one hormone; and optionally a powdered base;
wherein the at least one hormone is chosen from estriol, estradiol, estrone, or combination thereof; and wherein the composition is in a powdered form.
[0*090] The at least one hormone is a combination of estriol, estradiol, and estrone in a ratio of 5:4:1, 6:3:1, 7:2:1, or 8:1:1.
[00091] Examples of powdered bases suitable for use in the pharmaceutical compositions disclosed herein include, but are not limited to, talc, calcium carbonate, microcrystalline cellulose, powdered cellulose, dextrates, kaolin, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.
glom In another embodiment of the present invention, the at least one hormone is combined directly with the pharmaceutically acceptable carrier (ointment, cream, powder or gel base) without the prior use of a solvent or solvents.
[00093] In a further embodiment of the present invention, the hormone is weighed and packaged unadulterated in an appropriate container. The solvent or solvents and/or optionally the ointment, cream, gel base, or powdered base are packaged in a separate container. The two products are sold together as a kit. The two components are to be combined by whoever purchases the kit to formulate the hormone concentrate system.
[00094] Color coded-concentrated pharmaceutical composition [00095] The present invention also provides a color-coded concentrated hormone composition to help the pharmacist quickly choose the composition to be used.
[00096] The advantage of having color-coded concentrates are as follows:
helps to rapidly identify the concentrate.
ensures that all concentrates required to be contained in a final product are present in said final product. This is made possible because each combination and permutation of the concentrates will result in a distinct color profile. If the final product does not match the color profile for that medication, you know you have done something wrong; and ensures complete mixing of the final product. When the final product is a uniform color throughout, adequate mixing will have taken place.
[00097] The coloring agent could possibly be, but is not limited to one of the following: acid red 52, basic fuchsin USP, brilliant green, caramel NF, carmine NO.40, congo red, D&C green NO.5, D&C green NO.6, D&C green NO. 8, D&C orange NO.4, D&C red NO.4, D&C red NO.6, D&C red NO.17, D&C red NO.
22, D&C red NO.28, D&C red NO.33, D&C violet NO.2, D&C
yellow NO.8, D&C yellow NO.10, D&C yellow NO.11, F.D. &C.
blue NO.1, F.D. &C. blue NO.2, F.D. &C. green NO.3, F.D. &C.
red NO.3, F.D. &C. red NO.19, F.D. &C. red NO.40, F.D. &C.
yellow NO.5, F.D. &C. yellow NO.6, malachite green oxalate, rose Bengal, saffron, scarlet red, and any food color in liquid or powder form. The coloring agent is not particularly limited; any of those known in the pharmaceutical or cosmetic industries may be employed.
Preferably, the coloring agent will not noticeably color the skin. It should be compatible with the skin with the least number of adverse effects.
[00098] The concentrates according to the present invention would be manufactured using extensive safety measures. These include, but are not limited to, the use of custom built clean rooms (a room designed specifically for compounding with hazardous materials), high velocity air flow units fitted with high emission particulate air (HEPA) filters, custom built ventilation systems, protective suits, protective eyewear, protective gloves, and protective HEPA
filter masks.
[00099] A pharmacist or technician trained in the art of compounding BHRT ointments, creams, gels, and pastes will manufacture these concentrates.
gmolom An advantage of the present invention is the composition contains a high concentration of hormones (higher than the prescribed levels), thus the pharmacist can easily use the concentrates to produce a custom tailored BHRT product without risking his own health.
[000101] The present invention also contemplates a method for producing the concentrated composition of the present invention. The method comprises the steps of:
measuring at least one hormone, a solvent and/or optionally a carrier by using an electronic balance in a clean room;
combining the ingredients of step a by using an industrial scale mixer to ensure thorough mixing; and running the mixture of step b through a large-scale ointment mill or homogenizer to decrease the particle size of the drug, and optionally, heating the concentrate to facilitate the formation of a solution, wherein the hormone concentration is from about 0.6 to about 80%.
[000102] The concentrated hormone pharmaceutical composition of the present invention may be further divided with similar or different carrier materials to concentrations that are suitable for practical use by the compounding pharmacist.
[000103] If the medication is not thoroughly mixed, then it will not contain a uniform concentration of the drug throughout. A solution will provide the best distribution of drug throughout the system.
[000104] Running the mixture through a large-scale ointment mill or using a homogenizer decreases the particle size and increases the absorbability, because smaller drug particles will more readily penetrate the dermis. This process also ensures a non-gritty, pharmaceutically elegant, and cosmetically pleasing final product.
[00010] The present invention is also in combination with a dispensing device to provide a means to measure and combine, quickly and accurately, quantities of hormones with appropriate ointment, cream, or gel bases while minimizing exposure to hazardous airborne hormone particles. Thus, airborne particles are drastically reduced because the hormones are incorporated into a liquid or semi-solid form.
Example 1 [000106] The formulation was made in the following manner (total quantity: 120 ml and a concentration of 300mg/g of testosterone) 36g of testosterone were weighed out.
b) the volume was brought up to 120m1 with approximately 84 ml of an anhydrous gel base.
1 drop of blue food coloring was added.
the mixture was combined in an electronic mortar and pestle.
the mixture was run through an ointment mill to decrease the particle size of the testosterone.
the mixture was transferred into 4 30m1 luer lock syringes.
This is what the mixture is sold in.
Example 2 [000107] The formulation, according to the invention, was made in the following manner (total quantity: 1000m1 and a concentration of 62.5mg/g of triest (estriol, estradiol, and estrone in an 8:1:1 ratio) 50g of estriol were weighed out and wetted with 50m1 of ethoxy diglycol.
6.25g of estradiol were weighed out and wetted with 6.25m1 of ethoxy diglycol.
6.25g of estrone were weighed out and wetted with 6.25m1 of ethoxy diglycol.
drops of red food coloring was added.
the volume was brought up to 1000m1 with approximately 875m1 of oil in water emulsion type vanishing cream base.
the mixture was combined in an industrial mixer.
the mixture was run through an ointment mill to decrease the particle size of the estrogens.
the mixture was transferred into 33 30m1 luer lock syringes.
This is what the mixture is sold in.
=
Example 3 MOM] The formulation, according to the invention, was made in the following manner (total quantity: 5000 ml and a concentration of 400mg/g of progesterone) 2000g of progesterone were weighed out.
the progesterone was combined with an oil phase, an aqueous phase and an emulsifier to formulate a water in oil emulsion type cream base with a final volume (including the progesterone) of 5000m1.
50 drops of yellow food coloring was added.
the mixture was combined in an industrial mixer.
the mixture was run through an ointment mill to decrease the particle size of the progesterone.
the mixture was transferred into 83 60m1 luer lock syringes.
This is what the mixture is sold in.
Example 4 [000109] The formulation, according to the invention, was made in the following manner (total quantity: 10000 ml and a concentration of 600mg/g of progesterone (this is a paste) 6000g of progesterone were weighed out.
the progesterone was combined with 2000m1 of ethoxy diglycol.
100 drops of yellow food coloring was added.
an oil in water emulsion type vanishing cream base was used to bring the final volume to 10000m1, approximately 2900g of the cream.
the mixture was combined in an industrial mixer.
the mixture was run through an ointment mill to decrease the particle size of the progesterone.
the mixture was transferred into 50m1 ointment jar. This is what the mixture is sold in.
Example 5 [000110] The formulation, according to the invention, was made in the following manner (total quantity: 2000 ml and a concentration of 300mg/g of testosterone) 600g of testosterone were weighed out.
The testosterone was combined with approximately 400m1 of ethoxy diglycol.
15 drops of blue food coloring was added.
Approximately 1000m1 of a 1% hydroxypropylcellulose in ethoxy diglycol anhydrous gel was added to bring the final volume to 2000m1.
The mixture was combined in an industrial mixer.
The mixture was further mixed with a homogenizer to decrease the particle size of the testosterone.
The mixture was transferred to 40 50m1 bottles fitted with adapter caps. A 5m1 oral syringe and a lml oral syringe, fitting the adapter cap, were packaged with each bottle to be used as measuring devices.
Example 6 [000111] The formulation, according to the invention, was made in the following manner (total quantity: 10000m1 and a concentration of 40 mg/g of triest (estriol, estradiol, and estrone in an 8:1:1 ratio)) 320g of estriol were weighed out.
40g of estradiol were weighed out.
40g of estrone were weighed out.
100 drops of red food coloring was added.
The volume was brought up to 10000m1 with a 50% ethoxy diglycol and 50% propylene glycol combination.
The mixture was combined in an industrial mixer.
The mixture was heated to 60 degrees Celsius for 2 hours in order to facilitate solution of the triest powder.
The solution was transferred into 100 100m1 bottles fitted with adapter caps, accompanied with lml, 5m1, and 10m1 oral syringes. This is what the mixture is sold in.
Example 7 MOM The formulation, according to the invention, was made in the following manner (total quantity: 2000 ml and a concentration of 70mg/g of testosterone) 140g of testosterone were weighed out.
15 drops of blue food coloring was added.
The testosterone was combined with approximately 1860m1 of ethoxy diglycol, enough to bring the final volume to 2000m1.
The mixture was combined in an industrial mixer.
The mixture will now be a solution.
The solution was transferred to 40 50m1 bottles fitted with adapter caps. A 5m1 oral syringe and a lml oral syringe, fitting the adapter cap, were packaged with each bottle to be used as measuring devices.
Example 8 [00OW] The formulation, according to the invention, was made in the following manner (total quantity: 2000 ml and a concentration of 150mg/g of testosterone) 300g of testosterone were weighed out.
15 drops of blue food coloring was added.
The testosterone was combined with approximately 1700m1 of a 50% ethoxy diglycol and 50% propylene glycol mixture, enough to bring the final volume to 2000m1.
The mixture was heated to 60 degrees Celsius and mixed in an industrial mixer.
The mixture will now be a solution.
The solution was transferred to 40 50m1 bottles fitted with adapter caps. A 5m1 oral syringe and a lml oral syringe, fitting the adapter cap, were packaged with each bottle to be used as measuring devices.
[000114] Example 9 mom] The formulation, according to the invention, was made in the following manner (total quantity: 1000gm and a - _ concentration of 62.5mg/gm of triest (estriol, estradiol, and estrone in an 8:1:1 ratio)) 50g of estriol were weighed.
6.25g of estradiol were weighed out.
6.25g of estrone were weighed out.
The weight was brought up to 1000gm with approximately 937.5gm of lactose.
The mixture was combined in an industrial mixer.
The mixture was transferred to 10 100gm jars.
[000116] Example 10 [000117] The formulation, according to the invention, was made in the following manner (total quantity: 1000m1 and a concentration of 40mg/g of triest (estriol, estradiol, and estrone in an 8:1:1 ratio)) 32g of estriol were weighed out.
4g of estradiol were weighed out.
4g of estrone were weighed out.
The three powders were combined.
4g of this combination were transferred into each of 10 100m1 bottles fitted with adapter caps.
Approximately 96m1, enough to bring the final volume to 100m1, of a 50% ethoxy diglycol and 50% propylene glycol mixture was transferred to each of 10 other 100m1 bottles fitted with adapter caps.
The bottles could be sold as a kit or as 2 separate entities. 1 bottle of powder and 1 bottle of solvent would constitute 1 kit. The purchaser would add the solvent to the bottle containing the powder using an oral syringe so as not to be exposed to the powdered hormones. With stirring, at 50 degrees Celsius, the combination would form a solution. This solution is the hormone concentrate.
Example 11 [000118] The formulation, according to the invention, was made in the following manner (total quantity: 100m1 and a -concentration of 40mg/g of triest (estriol, estradiol, and estrone in an 8:1:1 ratio)) 3.2g of estriol were weighed out and transferred into a 100m1 bottle.
0.4g of estradiol were weighed out and transferred into a 100m1 bottle.
0.4g of estrone were weighed out and transferred into a 100m1 bottle.
Enough colored 50% propylene glycol/50% ethoxy diglycol mixture to combine with the estriol, estradiol, and estrone to bring the final volume to 100m1, approximately 96m1, was measured and transferred into a 100m1 bottle.
Example 12 [000119] The formulation, according to the invention, was made in the following manner (total quantity: 120 ml and a concentration of 300mg/g of testosterone) 36g of testosterone were weighed out.
The volume was brought up to 120m1 with approximately 84 ml of a glycerin.
1 drop of blue food coloring was added.
The mixture was combined in an electronic mortar and pestle.
The mixture was run through an ointment mill to decrease the particle size of the testosterone.
The mixture was transferred into 4 30m1 luer lock syringes. This is what the mixture is sold in.
[000120] The mixture of example 11 will be sold as a kit in which the pharmacist will combine the elements to produce the hormone concentrate system. The pharmacist will transfer the liquid into the bottle containing the estriol, then transfer this mixture into the bottle containing the estradiol, then transfer this mixture into the bottle containing the estrone. This final solution will be the triest concentrate.
[000121] These concentrates could be packaged in, or with, any graduated dispensing device that lends itself to accurately measure specific volumes of liquids or semi-solids including, but not limited to, a metered dose tube, a metered dose pump, a metered dose syringe, a bottle, an ointment jar, a metered dose spray bottle, a bottle fitted with an adapter cap, and a luer lock syringe, a pipette, a bottle top dispenser, a burette, and a metered dose scoop.
The packaging, dispensing, or measuring devices are not particularly limited. Any of those known in the pharmaceutical, chemical, or cosmetic industries may be used.
[000122] A specific amount, different for each compound, of these concentrates would be combined with an appropriate amount of any ointment, cream, or gel base, suitable for transdermal administration of bio-identical hormones, to form a final product which contains the doctor prescribed concentration of each bio-identical hormone.
[000123] The pharmacist using the concentrate, according to the invention, can easily incorporate the hormone into the compounding BERT ointments, creams, gels, or pastes by:
Putting on protective gloves.
Calculating the total amount of hormones needed to compound a medication of a specific volume and concentration depending on the patient necessities;
Determining how many milliliters of the appropriate concentrate will contain the total amount of hormone needed for the compound.
Measuring the volume of concentrate containing the total amount of hormone needed. This is done using an appropriate liquid or semi-solid measurement system.
Repeating steps 2 through 4 for each hormone to be present in the final preparation.
Calculating the amount of the appropriate ointment, cream, or gel base, which is needed for the final product.
This is accomplished by subtracting the total volume of concentrates used from the total volume needed.
Combining the ointment, cream, or gel base and the concentrates on a glass ointment slab, using an EMP, mixing them an appropriate number of times between two luer lock syringes attached together using a luer lock to luer lock adapter or any other form of mixing. When the color is uniform throughout, adequate mixing has taken place.
1000124] In another embodiment, the pharmaceutically acceptable carrier is sold inside a metered dose device.
These will make unnecessary to use a scale in measuring and making BHRT creams. This is a distinct advantage for pharmacies not presently engaged in the art of compounding.
The only additional equipment needed is a spatula for mixing. If the carrier is not packaged in a metered device, then the cream would have to be weighed and measured using a scale, which takes more time as well as additional cost to purchase the scale.
gam In addition, the invention concerns a kit for producing a concentrated hormone pharmaceutical composition, the kit comprising:
at least one hormone;
at least one solvent, and optionally a pharmaceutically acceptable carrier, wherein each element is packet in separated graduated dispensing devices.
[000126] In a further embodiment, the kit of the present invention comprises separately packing the at least one hormone and the at least one solvent in a container having internal divisions, wherein the at least one hormone and the at least one solvent are combined by the purchaser to form the hormone concentrate system.
[000127] Advantages [000128] The concentrated composition of the invention offers numerous advantages over compounding BHRT ointments, creams, gels, or pastes using a traditional method with commercially available hormones in powder form.
[WM Using these concentrates, combined with an appropriate liquid or semi-solid measurement system, in the place of powdered hormones and a scale, will dramatically reduce the risk of exposure to hazardous airborne hormone particles. This is due to the fact that the powdered hormones are incorporated into a liquid or semi-solid. This means that the need for inconvenient, expensive, and time-consuming safety measures is greatly reduced. Since there are relatively few airborne particles, there is little or no need for the use of custom built clean rooms (a room designed specifically for compounding with hazardous materials), high velocity air flow units fitted with HEPA
filters, custom built ventilation systems, protective suits, protective eyewear, or protective HEPA filter masks. The only safety measure definitely required is protective gloves.
[000130] When the concentrates are manufactured, they are mixed using an industrial mixer, which ensures thorough mixing. This alleviates the need for purchasing and using an EMP for compounding BHRT ointments, creams, gels, or pastes.
They are also run through a large ointment mill or homogenizer to reduce the particle size of the drug. This will increase absorbability, as smaller drug particles will more readily penetrate the dermis. This process also ensures a non-gritty, pharmaceutically elegant, and cosmetically pleasing product. This alleviates the need for purchasing and using an ointment mill for compounding BHRT ointments, creams, gels, or pastes.
[000131] The concentrates of the present invention offer the advantage that they are easier and most accurate to measure. The fact that the hormones are in solution results in a superior final product, the product produced from the concentrates and dispensed to the patient. This is due to the fact that there are no particles. All particles have been solubilized. This results in a pharmaceutically elegant and easily penetrateable final product.
[000132] The fact that the concentrates are color-coded will greatly reduce the chance of compounding errors. The color system should reduce the inadvertent use of one hormone concentrate instead of another. It will also ensure that all of the intended concentrates are present in the final product. This is accomplished because each combination and permutation of the concentrates will have a distinct color profile. If the final product does not match its profile, then you know something has been done incorrectly.
The color system will also help ensure that the final product is uniformly mixed. When the final product is a consistent color throughout, you will have adequate mixing.
At the present time, most compounding pharmacists do not have an adequate system in place to ensure proper mixing.
Without proper mixing, the final product will not have a uniform concentration of the hormones throughout the system.
Since the concentrate system alleviates the need for most of the safety measures required for compounding these medications, as well as the need for a scale, EMP, and ointment mill, it significantly reduces the cost of compounding these medications. The concentrate system also significantly decreases the time needed to compound them.
This is because the number of steps needed to compound them is drastically reduced. This increase in efficiency will result in a proportional decrease in labor costs.
[0001341 The hormone concentrates and an appropriate liquid or semi-solid measurement system will make it possible for any pharmacist in any setting to safely and accurately compound BHRT ointments, creams, gels, and pastes. At the present time, only compounding pharmacists with elaborate compounding facilities and the proper equipment can compound them safely and accurately. Using this invention, any pharmacist in any setting will now be able to safely, quickly, inexpensively, and accurately compound BERT
ointments, creams, gels, and pastes. This will inevitably result in an increase in the availability of these medications to the public.
[0001351 The fact that each final product, the product dispensed to the patient, has a distinct colour profile has an additional benefit. It will help decrease the chance of dispensing the wrong product to a patient. If a patient was to receive a Tri-est cream (which should be pink) but a blue cream was labeled Tri-Est, the pharmacist would be easily able to identify the error. Also, the patient would be able to tell that their previous cream was pink and this one is blue, bringing this to the pharmacist's attention. At present time all hormone creams are white, making it all but impossible to detect, a labeling error. The colour coding also decreases the likely hood of choosing the wrong cream from the stock as each cream is readily identifiable. The coloring system allows each final product to be differentiated from one another.
Claims (79)
1. A system for compounding pharmaceutical products for use in hormone replacement therapy, wherein the system comprises a plurality of customized hormone reagent compositions, each containing one or more steroid hormone(s) dissolved in one or more solvent(s);
wherein each of the reagent compositions is sufficiently uniform so that an amount of the hormone(s) in the composition can be accurately measured and dispensed to prepare a pharmaceutical product;
wherein the reagent compositions are sufficiently concentrated so that they may be combined with each other to create pharmaceutical products in which each hormone is wherein the concentration of each hormone in each pharmaceutical product made present in an amount that is customized for consumers having different therapeutic needs;
for each consumer using the system is therapeutically effective in accordance with their needs; and wherein each concentrated reagent composition is contained in a graduated dispensing- device.
wherein each of the reagent compositions is sufficiently uniform so that an amount of the hormone(s) in the composition can be accurately measured and dispensed to prepare a pharmaceutical product;
wherein the reagent compositions are sufficiently concentrated so that they may be combined with each other to create pharmaceutical products in which each hormone is wherein the concentration of each hormone in each pharmaceutical product made present in an amount that is customized for consumers having different therapeutic needs;
for each consumer using the system is therapeutically effective in accordance with their needs; and wherein each concentrated reagent composition is contained in a graduated dispensing- device.
2.
composition containing ethoxy diglycol and propylene glycol.
The system of claim 1, wherein the system comprises a concentrated reagent
composition containing ethoxy diglycol and propylene glycol.
The system of claim 1, wherein the system comprises a concentrated reagent
3. A system for compounding pharmaceutical products for use in hormone replacement therapy, wherein the system comprises a plurality of customized hormone reagent compositions, each containing one or more steroid hormone(s) dissolved in one or more solvent(s);
wherein each of the reagent compositions is sufficiently uniform so that an amount of the hormone(s) in the composition can be accurately measured and dispensed to prepare a pharmaceutical product;
wherein the reagent compositions are sufficiently concentrated so that they may be combined with each other to create pharmaceutical products in which each hormone is present in an amount that is customized for consumers having different therapeutic needs;
wherein the concentration of each hormone in each pharmaceutical product made for each consumer using, the system is therapeutically effective in accordance with their needs; and ethoxy diglycol and propylene glycol.
wherein each of the reagent compositions is sufficiently uniform so that an amount of the hormone(s) in the composition can be accurately measured and dispensed to prepare a pharmaceutical product;
wherein the reagent compositions are sufficiently concentrated so that they may be combined with each other to create pharmaceutical products in which each hormone is present in an amount that is customized for consumers having different therapeutic needs;
wherein the concentration of each hormone in each pharmaceutical product made for each consumer using, the system is therapeutically effective in accordance with their needs; and ethoxy diglycol and propylene glycol.
4. The system of claim 3, wherein each concentrated reagent composition is contained in a graduated dispensing device.
wherein the system comprises a concentrated reagent composition containing
wherein the system comprises a concentrated reagent composition containing
5. The pharmaceutical compounding system of any one of claims 1 to 4, comprising a concentrated reagent composition containing one or more estrogen(s) at a total concentration of at least 40 ma per gram.
comprising a separate reagent composition having a pharmaceutical carrier for combining comprising estradiol, and a concentrated reagent composition comprising estrone.
reagent composition containing a plurality of different estrogens at a total concentration
comprising a separate reagent composition having a pharmaceutical carrier for combining comprising estradiol, and a concentrated reagent composition comprising estrone.
reagent composition containing a plurality of different estrogens at a total concentration
6. The pharmaceutical compounding, system of claim 5, wherein said estrogen(5) are estriol, estradiol, or estrone.
7. The pharmaceutical compounding system of claims 5 or 6, comprising a concentrated of between 10 and 60 ma of estrogens per gram.
8. The pharmaceutical compounding system of any one of claims 5 to 7, comprising a plurality of concentrated reagent compositions, each containing a different estrogen.
9. The pharmaceutical compounding system of any one of claims 1 to 8, comprising a concentrated reagent composition comprising estriol and a concentrated reagent
10. The pharmaceutical compounding system of any one of claims 1 to 9, comprising, a concentrated reagent composition comprising estriol, a concentrated reagent composition
11. The pharmaceutical compounding system of any one of claims 1 to 10, wherein the composition comprising estradiol.
comprising a therapeutically effective amount of estriol, estradiol, and estrone at a ratio of 8:1:1, 5:4:1, 6:3:1, or 7:2:1 by weight.
concentrated reagent compositions can be compounded into a pharmaceutical product
comprising a therapeutically effective amount of estriol, estradiol, and estrone at a ratio of 8:1:1, 5:4:1, 6:3:1, or 7:2:1 by weight.
concentrated reagent compositions can be compounded into a pharmaceutical product
12. The pharmaceutical compounding system of any one of claims 1 to 11, comprising a at least 150 mg per gram.
concentrated reagent composition containing at least one androgen at a concentration of
concentrated reagent composition containing at least one androgen at a concentration of
13. The pharmaceutical compounding system of claim 12, wherein said androgen is testosterone or dehydroepiandrosterone (DHEA).
14. The pharmaceutical compounding system of any one of claims 1 to 13, comprising, a concentrated reagent composition at least one progestagen at a concentration of at least 200 mg per gram.
15. The pharmaceutical compounding system of claim 14, wherein said progestagen is progesterone or pregnenolone.
16. The pharmaceutical compounding system of any one of claims 1 to 15, further with the concentrated reagent compositions to produce a pharmaceutical product formulated as an ointment, cream, gel, or paste.
17. The pharmaceutical compounding system of any one of claims 1 to 16, wherein each of said concentrated reagent compositions is color coded.
18. The pharmaceutical compounding system of claim 17, wherein combination of some of said reagents into a particular pharmaceutical product produces a distinct color profile that can be used to confirm the identity of the hormone(s) in that product.
19.
compounding system of any one of claims 1 to 18.
compounding system of any one of claims 1 to 18.
20. A method for preparing the pharmaceutical compounding system of any one of claims A kit comprising the concentrated reagent compositions of the pharmaceutical 1 to 18, comprising for each of said reagent compositions:
a) combining steroid hormone(s) with penetration enhancing solvent(s); and b) processing said combination in an ointment mill or homogenizer to dissolve said hormone(s) in the solvent(s).
a) combining steroid hormone(s) with penetration enhancing solvent(s); and b) processing said combination in an ointment mill or homogenizer to dissolve said hormone(s) in the solvent(s).
21.
compounding system of any one of claims 1 to 18 in the manufacture of a medicament for hormone replacement therapy.
Use of a combination of the concentrated reagent composition of the pharmaceutic
compounding system of any one of claims 1 to 18 in the manufacture of a medicament for hormone replacement therapy.
Use of a combination of the concentrated reagent composition of the pharmaceutic
22. A concentrated liquid hormone composition for use in compounding a pharmaceutical product for topically delivering, one or more steroid hormones to a subject in need of hormone replacement therapy, comprising- one or more naturally occurring steroid homone(s) dissolved in a solvent mixture consisting of ethoxy diglycol and propylene glycol.
23. The concentrated liquid hormone composition of claim 22, wherein the solvent mixture is about 50% ethoxy diglycol and about 50% propylene glycol (vol/vol).
24.
estrogen(s) at a total concentration of at least 40 mg per gram.
The concentrated liquid hormone composition of claim 22, comprising one or more
estrogen(s) at a total concentration of at least 40 mg per gram.
The concentrated liquid hormone composition of claim 22, comprising one or more
25. The concentrated liquid hormone composition of claim 24, wherein said estrogen(s) are selected from estriol, estradiol, and estrone.
26.
27. The concentrated liquid hormone composition of claim 26, wherein said androgen is The concentrated liquid hormone composition of claim 22, comprising at least one selected from testosterone and dehydroepiandrosterone (DHEA).
androgen at a concentration of at least 150 mg per gram.
androgen at a concentration of at least 150 mg per gram.
28.
progestagen at a concentration of at least 200 mg per gram.
progestagen at a concentration of at least 200 mg per gram.
29. The concentrated liquid hormone composition of claim 28, wherein said progestagen The concentrated liquid hormone composition of claim 22, comprising at least one is selected from progesterone and pregnenolone.
30. A concentrated liquid hormone composition for use in compounding a pharmaceutical product for delivering hormones to a subject in need of hormone replacement therapy, comprising a plurality of different naturally occurring estrogens dissolved in a solvent mixture of ethoxy diglycol and propylene glycol at a total concentration of least 6 mg of estrogens per gram.
31. The concentrated composition of claim 30, wherein the composition comprises about 40 mg of estrogens per gram.
32. The concentrated composition of claim 31, wherein the estrogens are estriol, estradiol, and estrone.
33. The concentrated composition of claim 32, wherein the ratio of estriol, estradiol, and estrone by weight is 8:1:1,5:4:1,6:3:1, or 7:2:1.
34. A method for preparing the concentrated composition of any one of claims 22 to 33, comprising:
a) combining said steroid hormone(s) with said solvent(s); and b) processing said combination in an ointment mill or homogenizer to decrease particle size of said hormone(s) in the combination.
a) combining said steroid hormone(s) with said solvent(s); and b) processing said combination in an ointment mill or homogenizer to decrease particle size of said hormone(s) in the combination.
35. A plurality of concentrated hormone compositions according to any one of claims 22 to 33.
36. A method for compounding a pharmaceutical product for administering one or more hormones to a consumer in need of hormone replacement therapy, whereby the product is custom tailored for each individual consumer, the method comprising:
a) obtaining a plurality of concentrated liquid reagent compositions, each comprising one or more steroid hormone(s) dissolved in one or more solvent(s);
b) ascertaining the needs of an individual consumer; and c) compounding a plurality of said concentrated reagent composition(s) into said pharmaceutical product at a ratio that is custom tailored to the individual needs of said consumer, wherein the final concentration of each of said steroid hormone(s) in the pharmaceutical product is sufficient to be therapeutically effective for the consumer in accordance with their needs.
a) obtaining a plurality of concentrated liquid reagent compositions, each comprising one or more steroid hormone(s) dissolved in one or more solvent(s);
b) ascertaining the needs of an individual consumer; and c) compounding a plurality of said concentrated reagent composition(s) into said pharmaceutical product at a ratio that is custom tailored to the individual needs of said consumer, wherein the final concentration of each of said steroid hormone(s) in the pharmaceutical product is sufficient to be therapeutically effective for the consumer in accordance with their needs.
37. The concentrated liquid hormone composition of claim 36, wherein the solvent mixture is about 50% ethoxy diglycol and about 50% propylene glycol (vol/vol).
38. The compounding method of claim 36, wherein at least one of the concentrated reagent compositions contains one or more estrogen(s) dissolved at a total concentration of at least 40 ma per gram.
39. The compounding method of claim 38, wherein said estrogen(s) are selected from estriol, estradiol, and estrone.
40. The compounding method of claim 36, wherein at least one of the concentrated reagent compositions contains at least one androgen at a concentration of at least 150 mg per gram.
41. The compounding method of claim 40, wherein said androgen is selected from testosterone and dehydroepiandrosterone (DHEA).
42. The compounding method of claim 36, wherein at least one of the concentrated reagent compositions contains at least one progestagen at a concentration of at least 200 mg per gram.
43. The compounding method of claim 42, wherein said progestagen is selected from progesterone and pregnenolone.
44. The compounding method of claim 36, comprising combining a plurality of concentrated reagent compositions, each containing a different estrogen.
45. The compounding method of claim 36, whereby the pharmaceutical product produced contains estriol and estradiol.
46. The compounding method of claim 45, wherein the ratio of estriol:estradiol by weight in the final product is 5:5, 6:4, 7:3, 8:2, or 9:1.
47. The compounding method of claim 36, whereby the pharmaceutical product produced contains estriol, estradiol, and estrone.
48. The compounding method of claim 47, wherein the ratio of estriol, estradiol, and estrone by weight in the final product is 8:1:1,5:4:1,6:3:1, or 7:2:1.
49. The compounding method of claim 36 in which one or more of said concentrated reagent the hormone(s) in the product according to the colour of the pharmaceutical product after compounding.
composition(s) is color-coded, and the method further comprises verifying the identity of
composition(s) is color-coded, and the method further comprises verifying the identity of
50. The compounding method of claim 36 in. which one or more of said concentrated final product is a uniform color throughout.
reagent composition(s) is color coded, and the method further comprises verifying that
reagent composition(s) is color coded, and the method further comprises verifying that
51. A system for compounding_ pharmaceutical products for use in hormone replacement the ingredients of the product have been adequately mixed according to whether the therapy, wherein the system comprises a plurality of customized hormone reagent compositions, each containing one or more steroid hormone(s) dissolved in one or more solvent(s);
wherein each of the reagent compositions is sufficiently uniform so that an amount of the hormone(s) in the composition can be accurately measured and dispensed to prepare a pharmaceutical product;
wherein the reagent compositions are sufficiently concentrated so that they may be combined with each other to create pharmaceutical products in which each hormone is present in an amount that is customized for consumers having different therapeutic needs;
wherein the concentration of each hormone in each pharmaceutical product made for each consumer using the system is therapeutically effective in accordance with their needs.
wherein each of the reagent compositions is sufficiently uniform so that an amount of the hormone(s) in the composition can be accurately measured and dispensed to prepare a pharmaceutical product;
wherein the reagent compositions are sufficiently concentrated so that they may be combined with each other to create pharmaceutical products in which each hormone is present in an amount that is customized for consumers having different therapeutic needs;
wherein the concentration of each hormone in each pharmaceutical product made for each consumer using the system is therapeutically effective in accordance with their needs.
52. A system for compounding pharmaceutical products for use in hormone replacement therapy, wherein the system comprises a plurality of customized hormone reagent compositions, each containing one or more steroid hormone(s) dissolved in one or more solvent(s);
wherein each of the reagent compositions is sufficiently uniform so that an amount of the hormone(s) in the composition can be accurately measured and dispensed to prepare a pharmaceutical product;
wherein the reagent compositions are sufficiently concentrated so that they may present in an amount that is customized for consumers having different therapeutic needs;
be combined with each other to create pharmaceutical products in which each hormone is wherein the concentration of each hormone in each pharmaceutical product made for each consumer using the system is therapeutically effective in accordance with their needs.
wherein each of the reagent compositions is sufficiently uniform so that an amount of the hormone(s) in the composition can be accurately measured and dispensed to prepare a pharmaceutical product;
wherein the reagent compositions are sufficiently concentrated so that they may present in an amount that is customized for consumers having different therapeutic needs;
be combined with each other to create pharmaceutical products in which each hormone is wherein the concentration of each hormone in each pharmaceutical product made for each consumer using the system is therapeutically effective in accordance with their needs.
53.
composition containing ethoxy diglycol and propylene glycol.
The system of claim 51 or 52, wherein the system comprises a concentrated reagent
composition containing ethoxy diglycol and propylene glycol.
The system of claim 51 or 52, wherein the system comprises a concentrated reagent
54.
The system of any one of claims 51 to 53, wherein each concentrated reagent
The system of any one of claims 51 to 53, wherein each concentrated reagent
55.
concentrated reagent composition containing one or more estrogen(s) at a total concentration of at least 40 ma per gram.
composition is contained in a graduated dispensing device.
concentrated reagent composition containing one or more estrogen(s) at a total concentration of at least 40 ma per gram.
composition is contained in a graduated dispensing device.
56. The pharmaceutical compounding system of claim 55, wherein said estrogen(s) are estriol, estradiol, or estrone.
57. The pharmaceutical compounding system of claims 55 or 56, comprising a concentrated reagent composition containing a plurality of different estrogens at a total concentration The pharmaceutical compounding system of any one of claims 51 to 54, comprising a of between 10 and 60 ma of estrogens per gram.
58. The pharmaceutical compounding system of any one of claims 55 to 57, comprising a plurality of concentrated reagent compositions, each containing a different estrogen.
59.
The pharmaceutical compounding system of any one of claims 51 to 58, comprising a concentrated reagent composition comprising estriol and a concentrated reagent composition comprising estradiol.
The pharmaceutical compounding system of any one of claims 51 to 58, comprising a concentrated reagent composition comprising estriol and a concentrated reagent composition comprising estradiol.
60.
The pharmaceutical compounding system of any one of claims 51 to 59, comprising a concentrated reagent composition comprising estriol, a concentrated reagent composition comprising estradiol, and a concentrated reagent composition comprising estrone.
The pharmaceutical compounding system of any one of claims 51 to 59, comprising a concentrated reagent composition comprising estriol, a concentrated reagent composition comprising estradiol, and a concentrated reagent composition comprising estrone.
61.
The pharmaceutical compounding system of any one of claims 51 to 60, wherein the concentrated reagent compositions can be compounded into a pharmaceutical product comprising a therapeutically effective amount of estriol, estradiol, and estrone at a ratio of 8:1:1, 5:4:1, 6:3:1, or 7:2:1 by weight.
The pharmaceutical compounding system of any one of claims 51 to 60, wherein the concentrated reagent compositions can be compounded into a pharmaceutical product comprising a therapeutically effective amount of estriol, estradiol, and estrone at a ratio of 8:1:1, 5:4:1, 6:3:1, or 7:2:1 by weight.
62.
The pharmaceutical compounding system of any one of claims 51 to 61, comprising a concentrated reagent composition containing at least one androgen at a concentration of at least 150 mg per gram.
The pharmaceutical compounding system of any one of claims 51 to 61, comprising a concentrated reagent composition containing at least one androgen at a concentration of at least 150 mg per gram.
63.
The pharmaceutical compounding system of claim 62, wherein said androgen is testosterone or dehydroepiandrosterone (DHEA).
The pharmaceutical compounding system of claim 62, wherein said androgen is testosterone or dehydroepiandrosterone (DHEA).
64.
The pharmaceutical compounding system of any one of claims 51 to 63, comprising a concentrated reagent composition at least one progestagen at a concentration of at least 200 mg per gram.
The pharmaceutical compounding system of any one of claims 51 to 63, comprising a concentrated reagent composition at least one progestagen at a concentration of at least 200 mg per gram.
65.
The pharmaceutical compounding system of claim 64, wherein said progestagen is progesterone or pregnenolone.
The pharmaceutical compounding system of claim 64, wherein said progestagen is progesterone or pregnenolone.
66.
The pharmaceutical compounding system of any one of claims 51 to 65, further comprising a separate reagent composition having a pharmaceutical carrier for combining with the concentrated reagent compositions to produce a pharmaceutical product formulated as an ointment, cream, gel, or paste.
The pharmaceutical compounding system of any one of claims 51 to 65, further comprising a separate reagent composition having a pharmaceutical carrier for combining with the concentrated reagent compositions to produce a pharmaceutical product formulated as an ointment, cream, gel, or paste.
67.
The pharmaceutical compounding system of any one of claims 51 to 66, wherein each of said concentrated reagent compositions is color coded.
The pharmaceutical compounding system of any one of claims 51 to 66, wherein each of said concentrated reagent compositions is color coded.
68.
The pharmaceutical compounding system of claim 67, wherein combination of some of said reagents into a particular pharmaceutical product produces a distinct color profile that can be used to confirm the identity of the hormone(s) in that product.
The pharmaceutical compounding system of claim 67, wherein combination of some of said reagents into a particular pharmaceutical product produces a distinct color profile that can be used to confirm the identity of the hormone(s) in that product.
69.
A kit comprising the concentrated reagent compositions of the pharmaceutical compounding system of any one of claims 51 to 68.
A kit comprising the concentrated reagent compositions of the pharmaceutical compounding system of any one of claims 51 to 68.
70.
A method for preparing the pharmaceutical compounding system of any one of claims 51 to 68, comprising for each of said reagent compositions:
a) combining steroid hormone(s) with penetration enhancing solvent(s); and b) processing said combination in an ointment mill or homogenizer to dissolve said hormone(s) in the solvent(s).
A method for preparing the pharmaceutical compounding system of any one of claims 51 to 68, comprising for each of said reagent compositions:
a) combining steroid hormone(s) with penetration enhancing solvent(s); and b) processing said combination in an ointment mill or homogenizer to dissolve said hormone(s) in the solvent(s).
71. Use of a combination of the concentrated reagent composition of the pharmaceutical compounding system of any one of claims 51 to 70 in the manufacture of a medicament for hormone replacement therapy.
72. A concentrated liquid hormone composition for use in compounding a pharmaceutical product for delivering one or more steroid hormones to a subject in need of hormone replacement therapy, comprising one or more naturally occurring steroid hormone(s).
73. The concentrated liquid hormone composition of claim 72, wherein the solvent mixture is about 50% ethoxy diglycol and about 50% propylene glycol (vol/vol).
74. The concentrated liquid hormone composition of claim 72, comprising one or more estrogen(s) at a total concentration of at least 40 mg per gram.
75. The concentrated liquid hormone composition of claim 74, wherein said estrogen(s) are selected from estriol, estradiol, and estrone.
76. The concentrated liquid hormone composition of claim 72, comprising at least one androgen at a concentration of at least 150 mg per gram.
77. The concentrated liquid hormone composition of claim 76, wherein said androgen is selected from testosterone and dehydroepiandrosterone (DHEA).
78. The concentrated liquid hormone composition of claim 72, comprising at least one
79. The concentrated liquid hormone composition of claim 78, wherein said progestagen progestagen at a concentration of at least 200 mg per gram.
is selected from progesterone and pregnenolone,
is selected from progesterone and pregnenolone,
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45491503P | 2003-03-14 | 2003-03-14 | |
US60/454915 | 2003-03-14 | ||
US10/668075 | 2003-09-22 | ||
US10/668,075 US7858607B2 (en) | 2003-03-14 | 2003-09-22 | System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2459869A1 CA2459869A1 (en) | 2004-09-14 |
CA2459869C true CA2459869C (en) | 2013-05-21 |
Family
ID=32965766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2459869A Expired - Lifetime CA2459869C (en) | 2003-03-14 | 2004-03-05 | A system for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2459869C (en) |
-
2004
- 2004-03-05 CA CA2459869A patent/CA2459869C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2459869A1 (en) | 2004-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7858607B2 (en) | System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer | |
US20190254927A1 (en) | Topical pharmaceutical compounds and methods | |
Bhalla et al. | Hypercalcemia caused by iatrogenic hypervitaminosis A | |
DiLiberti et al. | Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen | |
JPH0465051B2 (en) | ||
CA2459869C (en) | A system for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer | |
US20230372327A1 (en) | Pharmaceutical composition based on nalbuphine and/or its salts for nasal administration | |
CN103054830B (en) | Soft capsule for treating nerve diseases | |
CN104274391B (en) | Rifaximin-containing pharmaceutical preparation | |
Cisternino et al. | Stability of fludrocortisone acetate solutions prepared from tablets and powder | |
Morgan et al. | Metered-dose transdermal spray (MDTS) | |
US5340805A (en) | Danazol for treatment of urinary incontinence | |
JP3723728B2 (en) | Skin topical solution | |
Feldschuh | Compounding in community pharmacy | |
Blair | Liposomal cannabidiol delivery: A pilot study | |
CN1509720A (en) | Progesterone capsule and preparing method thereof | |
US11622947B2 (en) | Compositions comprising quillaja extract and methods of preparations and use thereof | |
CN111529491B (en) | Quick-acting safe ticagrelor oral spray and preparation method thereof | |
CN104288157B (en) | Solid dispersions comprising clobetasol propionate and Tretinoin and preparation method thereof | |
JPH05178753A (en) | External preparation for skin pruritus | |
Abdallah et al. | Availability and Stability of Crushed Warfarin Tablet in Different Solvents | |
Lantink et al. | Raw Materials | |
Behlim | Development & Validation of Analytical Method for the Assay of Etoposide in Its Raw Material Using Reversed-Phase High Performance Liquid Chromatography | |
Suárez González | Desarrollo y caracterización de formulaciones farmacéuticas adaptadas para pediatría: medicamentos antituberculosos | |
Yadav et al. | Pharmaceutics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |